Folate deficiency …

Douglas J Lanska MD MS MSPH

Neurogenetic Disorders

Updated 05.14.2024
Released 11.06.2012
Expires For CME 05.14.2027

Folate deficiency

Author: Douglas J Lanska MD MS MSPH

See Contributor Disclosures

Folate deficiency

In This Article

Quick Link

Introduction

Overview

Folate deficiency is characterized by megaloblastic anemia and less frequently by neurologic problems, usually forgetfulness and irritability, but sometimes by neuropathy or myelopathy. Maternal folate deficiency early in pregnancy is also a major risk factor for fetal neural tube defects. Folate deficiency may arise as the result of dietary deficiency or generalized malabsorption, such as in sprue or celiac disease. A small number of affected individuals have hereditary folate malabsorption due to mutations in the SLC46A1 gene, which encodes the proton-coupled folate transporter responsible for folate transport across the intestinal epithelia and the blood-brain barrier.

Key points

	• Derivatives of folic acid are required for nucleic acid and amino acid metabolism.
	• Folate deficiency results in megaloblastic anemia and neurologic problems.
	• Folate deficiency is observed in individuals with insufficient dietary folate, decreased uptake due to intestinal disease, or alcoholism.
	• Folic acid fortification of cereal grains in the United States and some other countries means that dietary folate deficiency is becoming less common.
	• A small number of patients with hereditary folate malabsorption due to mutations in the SLC46A1 gene have been identified.

Historical note and terminology

Dietary folate deficiency was first reported in 1931 by English physician Lucy Wills (1888–1964), who described megaloblastic anemia, identical to that seen in patients with pernicious anemia, among nutritionally deficient women at a hospital in India (164; 09; 157; 124; 19; 90).

English physician Lucy Wills (1888-1964)

In 1931, Wills described megaloblastic anemia, identical to that seen in patients with pernicious anemia, among nutritionally deficient women at a hospital in India. This nutritional deficiency was later shown to be due to fola...

Subsequent studies resulted in isolation of the missing dietary factor and determination of its structure (08). The first patient with a genetic disorder resulting in specific inability to absorb dietary folate was described in 1961 (97).

The classic study of experimental human folate deficiency was self-experimentation by American hematologist Victor Herbert (1927-2002) (72; 66). Decreased serum folate concentrations could be detected after 3 weeks of folate deprivation. Hypersegmented neutrophils were the first evident hematological anomaly, after 7 weeks of deprivation. Macrocytosis of circulating red cells was observed after 18 weeks. Anemia developed rapidly after 4.5 months on a folate-deficient diet. In this case, leukopenia and thrombocytopenia did not occur. Sleeplessness and forgetfulness occurred during the fourth month of folate deprivation, and irritability occurred during the fifth month; this latter problem became progressively worse. All of these manifestations of folate deficiency responded rapidly to oral therapy with folic acid.

Folic acid (also called pteroylglutamic acid) is a stable molecule that is not itself active metabolically.

Folic acid (chemical structure, skeleton formula)

Image by Calvero (2006). (Courtesy of Wikimedia Commons. Public domain.)
Three-dimensional ball-and-stick model of folic acid

Black=Carbon; White=Hydrogen; Red=Oxygen; Blue=Nitrogen. Image by Jynto (2011). (Courtesy of Wikimedia Commons. Creative Commons CC0 1.0 Universal Public Domain Dedication.)

It must be converted within cells to a number of reduced derivatives that are required for 1-carbon transfer reactions involved in cellular intermediary metabolism. The term “folate” refers to folic acid and its derivatives.

The term “folate” is frequently used in a generic sense to designate any member of the pteroylglutamate family or their derivatives, which have various reduction levels of the pteridine ring, as well as different numbers of glutamate residues and 1-carbon substitutions (153). The term, therefore, includes folic acid, the biologically active form tetrahydrofolate (THF), the main circulating form 5-methyltetrahydrofolate (5-MTHF), folinic acid (5-formyltetrahydrofolate; leucovorin), and others.

Clinical manifestations

Presentation and course

	• Folate deficiency has classically been recognized by the presence of megaloblastic anemia, which is morphologically indistinguishable from that seen in vitamin B12 (cobalamin) deficiency.
	• Neurologic changes have been reported less frequently in folate-deficient individuals than in vitamin B12-deficient individuals.
	• Although the frequency of neuropsychiatric involvement may be similar in folate-deficient and vitamin B12-deficient individuals, the severity of the clinical abnormalities is usually much greater in those with vitamin B12 deficiency.
	• The most frequent neurologic findings in folate-deficient individuals have been forgetfulness, irritability, and depression; neuropathy and, rarely, myelopathy and brain atrophy have also been reported.
	• The neuropathy associated with folate deficiency is usually a slowly progressive, large-fiber, axonal polyneuropathy with predominant involvement of the lower extremities, sensory rather than motor involvement, and predominant deep rather than superficial sensory loss.
	• Folate deficiency is common in epileptic children treated chronically with antiepileptic drugs, contributes to poor seizure control, and should be considered in the etiologic differentials of drug-resistant epilepsy; importantly, folate supplementation improves seizure control in these children.
	• Folate deficiency in infants can occur in hereditary folate malabsorption and may be associated with severe neurologic deterioration, which can be irreversible if the condition is not diagnosed and treated in a timely manner.

Folate deficiency has classically been recognized by the presence of megaloblastic anemia, which is morphologically indistinguishable from that seen in vitamin B12 (cobalamin) deficiency (90).

Neurologic changes have been reported less frequently in folate-deficient individuals than in vitamin B12-deficient individuals. Although the frequency of neuropsychiatric involvement may be similar in the two groups, the severity of the clinical abnormalities is usually much greater in those with vitamin B12 deficiency (132). The most frequent neurologic findings in folate-deficient individuals have been forgetfulness, irritability, and depression; neuropathy and, rarely, myelopathy and brain atrophy have also been reported (27; 49; 99; 96; 90; 122; 88; 82; 87).

The neuropathy associated with folate deficiency is usually a slowly progressive, large-fiber, axonal polyneuropathy with predominant involvement of the lower extremities, sensory rather than motor involvement, and predominant deep rather than superficial sensory loss (88; 89). In patients with neuropathy, macrocytosis is present in a minority, and few have moderate or severe anemia (88). Compared with patients who had thiamine-deficiency neuropathy (ie, beriberi), patients with folate-deficiency neuropathy showed significantly slower progression, preferential sensory manifestations, predominant deep sensory loss, and relatively preserved biceps tendon reflexes (88). Unusual presentations have included a relapsing radial nerve palsy, which followed diarrheic episodes and responded in a dramatic fashion to folate therapy (27).

Folate deficiency is common in epileptic children treated chronically with antiepileptic drugs; it contributes to poor seizure control and should be considered in the etiologic differentials of drug-resistant epilepsy. Importantly, folate supplementation improves seizure control in these children (46).

Folic acid deficiency during pregnancy interferes with closure of the neuropore. Folic acid deficiency is, therefore, an important risk factor for neural tube defects (38; 158).

Closure of the neuropore

A pencil drawing showing the sequence of events, which lead to the closure of the embryonic neuropore. The neuropore refers to the opening (anterior or posterior) of the developing neural tube. (Drawing by Heather Spears. Court...
Anencephaly

Anencephaly is a fatal neural tube defect in which the cerebral hemispheres do not develop, although some highly disorganized brainstem tissue is typically present. Prenatal screening for neural tube defects has significantly d...
Anencephaly in stillborn (x-ray)

(Photography by Lucien Monfils on July 24, 2008. GNU Free Documentation License.)

There is an inverse association between folate levels and first stroke in individuals who have never smoked, but no such association has been found among individuals who have smoked (172). Folic acid therapy significantly reduced the risk of first stroke in never smokers with folate deficiency and in ever smokers with normal folate levels. Compared with never smokers, ever smokers may require a higher dosage of folic acid to achieve a protective effect against stroke.

Other possible manifestations of folate deficiency include cutaneous hyperpigmentation, erectile dysfunction, premature ejaculation, carcinogenesis, and aneuploidy (166; 80; 114). In cultured human colon cells, Guo and colleagues showed that folate deficiency induces mitotic aberrations and chromosomal instability (by compromising the spindle assembly checkpoint) (65). Folate deficiency may also result in aberrant DNA methylation profiles that influence cancer-related gene expression (104). Concern has also been raised that folate supplementation may also increase the risk of certain cancers (167), although there is a protective effect for folic acid supplementation on the development of colorectal cancer in patients with inflammatory bowel disease, as demonstrated in a metaanalysis by Burr and colleagues (29), and maternal folic acid supplementation before and during pregnancy seems to confer protection against the risk of childhood leukemia in offspring (32). In addition, mothers with polymorphisms in folate-homocysteine pathway genes are more likely to have children with Down syndrome, a genotypic risk that can potentially be mitigated by periconceptional nutritional supplementation (141).

Folate deficiency in infants can occur in hereditary folate malabsorption and may be associated with severe neurologic deterioration, which can be irreversible if the condition is not diagnosed and treated in a timely manner (59; 159; 143; 07). During infancy, a Chinese boy with hereditary folate malabsorption developed macrocytic anemia, leukopenia, thrombocytopenia, recurrent pneumonia, diarrhea, mouth ulcers, and progressive neurologic deterioration (143). Neurologic symptoms were recognized by 10 months of age as medication-resistant epilepsy and delayed motor and cognitive development. Magnetic resonance imaging at 10 months of age revealed cerebellar atrophy and generalized broadening of the cerebral sulcus. By 18 months, he could sit by himself, but he could not stand or walk unassisted due to gait instability, and he could not vocalize anything except “pa-pa” and “ma-ma.”

Biological basis

	• Folate from natural food sources has poor stability and incomplete bioavailability compared with folic acid, the synthetic form of the vitamin.
	• Derivatives of folic acid are required for a number of 1-carbon transfer reactions, including two separate steps in the de novo synthesis of purines, conversion of deoxyuridine triphosphate to thymidine triphosphate, and methylation of homocysteine to form methionine.
	• Folate deficiency most frequently develops when there is insufficient folate in the diet or when the body is unable to absorb dietary folate. Inability to absorb folate may develop in various intestinal diseases and conditions in which uptake of multiple nutrients may be impaired.
	• In folate deficiency, impaired nucleotide synthesis is likely responsible for the megaloblastic anemia, which is characterized by abnormal DNA synthesis in rapidly proliferating tissues.
	• Antifolates medications disrupt the metabolic pathways that require 1-carbon moieties supplied by folate.
	• A small number of individuals have hereditary folate malabsorption and develop folate deficiency during the first months of life as a result of mutations in the SLC46A1 (solute carrier family 46 member 1) gene, located on chromosome 17q11.2, which encodes the proton-coupled folate transporter.
	• Folate deficiency is known to contribute to neural tube and neural crest defects.
	• Expansion of a CGG trinucleotide repeat sequence in the FRAXA locus associated with fragile X syndrome exhibits fragility in response to folate deficiency or other forms of "folate stress."
	• Mothers with polymorphisms in folate-homocysteine pathway genes are more likely to have children with Down syndrome, a genotypic risk that can potentially be mitigated by periconceptional nutritional supplementation.

Etiology and pathogenesis

Folic acid and "folates.” The core of the folic acid (pteroylglutamic acid) molecule is a heterocyclic pterin structure.

Skeletal formula of a pterin ring structure

(Public domain.)

Pterin is a heterocyclic compound composed of a pteridine ring system, with a "keto group" (a lactam) and an amino group on positions 4 and 2, respectively. It is structurally related to the parent bicyclic heterocycle called pteridine. Pterins, as a group, are compounds related to pterin with additional substituents. Pterins exist in different tautomeric forms (ie, interchangeable isomers of a molecule resulting from spontaneous rearrangement of chemical bonds in solution or in a cell) that differ in shape, functional groups, and hydrogen-bonding pattern.

Pterin tautomerism

(Public domain.)

In folic acid, the pterin structure has a methyl group in the sixth position and is bound to para-aminobenzoic and glutamic acid. Historic names included the L. ⁠casei factor vitamin Bc, and vitamin M.

Schematic diagram of the folic acid family of enzymatic cofactors

(Source: Diagram by Boghog courtesy of Wikimedia Commons. Creative Commons Attribution-Share Alike 4.0 International license.)

"Folate" (vitamin B9) refers collectively to folic acid and its multiple biologically active derivatives, including dihydrofolic acid, tetrahydrofolic acid (the active form), 5-methyltetrahydrofolate (the primary form found in blood), and 5,10-methylenetrahydrofolate.

Skeletal formula of dhydrofolic acid

(Public domain.)
Skeletal formula of tetrahydrofolic acid

(Public domain.)
Skeletal formula of methyltetrahydrofolate

(Public domain.)
Skeletal formula of 5,10-methenyltetrahydrofolate

(Public domain.)

Folate from natural food sources has poor stability and incomplete bioavailability compared with folic acid.

Intestinal folate absorption

Absorption of dietary folates takes place in the duodenum and proximal jejunum. A preliminary step for intestinal folate absorption is hydrolysis of polyglutamated folates by glutamate carboxypeptidase II in the enterocyte brush border.

Overview of folate-homocysteine metabolism

Humans can obtain folate from food or food supplements (folic acid [FA] and 5-methyltetrahydrofolate [5-Me-THF]). Folates from food are polyglutamates, which must be hydrolyzed to monoglutamates by the enzyme glutamate carboxyp...

Hydrolysis and absorption are optimal at low pH, which is provided by intestinal Na+/H+ exchangers. Monoglutamates from dietary sources are then transported intracellularly from the lumen of the proximal small intestine by the proton-coupled folate transporter (PCFT), whereas folates from supplementation are transported intracellularly from the lumen of the proximal small intestine by the reduced folate carrier (RFC; folate transporter 1; SLC19A1 [Solute Carrier Family 19 Member 1]).

Schematic location and functioning of the PCFT in the proximal jejumun and colon

In the diagram, an apical surface of polarized epithelial cells is marked by irregular contour.

Legend: DHF: dihydrofolate; 5-formyl-THF: 5-formyl-tetrahydrofolate; H+: hydrogen i...
Schematic location and functioning of the RFC in hepatocytes, small intestine, colon, and epithelial cells of the choroid plexus

Folates from supplementation (eg, folic acid and 5-methyl-THF) are transported intracellularly from the lumen of the proximal small intestine by the reduced folate carrier (RFC; folate transporter 1; SLC19A1 [Solute Carrier Fam...

Folate cellular uptake

Folates are partially hydrophilic anions that do not easily diffuse across biological membranes, so various transporters are used by different cells and tissues.

Renal reabsorption of folates from glomerular filtrate. Renal reabsorption of folates from glomerular filtrate in the proximal tubules relies on the high-affinity folate receptor FRα through a process of transcytosis (127; 133).

Schematic location and functioning of cellular folate transporters FRα and PCFT in the transcytosis of folate in the renal tubular epithelium

Schematic location and functioning of cellular folate transporters FRα and PCFT in the transcytosis of folate in the renal tubular epithelium}{label:Renal reabsorption of folates from glomerular filtrate in the proximal tubules...

Transcytosis is a type of transcellular transport in which macromolecules are captured in vesicles on one side of the cell, drawn across the cell, and ejected on the other side. In the case of folate transcytosis, transfer of folates from the renal tubular epithelium to the blood apparently utilizes the proton-coupled folate transporter (PCFT) (127; 133).

The folate-specific transporters reduced folate carrier (RFC) and proton-coupled folate transported (PCFT) are highly expressed in the proximal renal tubule, with known expression of RFC at the basolateral membrane (127), although RFC may also be present at the apical membrane (133).

RFC functions on the basolateral membranes of the renal tubular epithelium to transport 5-methyl-THF

Additional low-affinity, high-capacity folate transporters expressed at the apical and basolateral membranes may also contribute to renal folate transport (127). At the apical membrane, low-affinity, high-capacity folate transporters include the multidrug resistance-associated proteins (MRPs) efflux pumps 2 and 4 and the organic anion transporters (OAT) K1, K2, and 4, and the efflux transporter BCRP (Breast Cancer Resistance Protein) (127; 133). At the basolateral membrane, low-affinity, high-capacity folate transporters include OAT1, OAT2, and OAT3 as well as the efflux pump MRP3 (and possibly MRPs 1 and 5) (127; 133).

Low-affinity, high-capacity folate transporters in the renal tubular epithelium

Low-affinity, high-capacity folate transporters expressed at the apical and basolateral membranes of the renal tubular epithelium also contribute to renal folate transport.

Legend: BCRP: breast cancer re...

The multifunctional endocytic receptors megalin, which binds soluble folate binding proteins (FBP), and cubilin, which binds albumin (ALB), may also be involved in the uptake of folates under conditions of folate deficiency (127).

A global scheme of renal resorption of folates from glomerular filtrate was illustrated by Samodelov and colleagues (127).

Renal reabsorption of folates from glomerular filtrate

Renal reabsorption of folates from glomerular filtrate in the proximal tubules under physiological conditions is thought to rely on the high-affinity folate receptor FRα through a process of transcytosis to the basolateral memb...

Folate metabolism. Derivatives of folic acid are required for multiple 1-carbon transfer reactions, including two separate steps in the de novo synthesis of purines (catalyzed by glycinamide ribonucleotide transformylase and amino-4-imidazolecarboxamide ribonucleotide transformylase), conversion of deoxyuridine triphosphate to thymidine triphosphate (thymidylate synthase), and methylation of homocysteine to form methionine (methionine synthase) (54).

Folate and folate-mediated one-carbon metabolism

The one-carbon units carried by reduced folate are involved in cytosolic, mitochondrial, and nuclear folate pools and used for the biosynthesis of purines, thymidylate, amino acids, and S-adenosylmethionine (SAM). Over-expresse...

Both purines and thymidine are required for synthesis of DNA, and purines for the synthesis of RNA. Methionine is required for protein synthesis; it is also converted to S-adenosylmethionine, which is the methyl-group donor in a variety of transmethylation reactions, including methylation of DNA, RNA, proteins, and numerous small molecules, including steps involved in synthesis of the neurotransmitters epinephrine, norepinephrine, and dopamine.

The folate cycle

Folate is a precursor for tetrahydrofolate, which (1) serves as a carbon donor; (2) acts as a cofactor; and (3) is important for nucleic acid and amino acid syntheses.

The folate cycle is actually more than one set of cyclic biochemical interconversions involving metabolites of folate. The cyclic interconversions of the folate cycle are closely connected with thymidine synthesis (needed for DNA synthesis), trans-sulfuration, methionine synthesis (remethylation from homocysteine), and the methylation cycle (used for control of genes).

Simplified schematic diagram of the folate cycle

The folate cycle is actually more than one set of cyclic biochemical interconversions involving metabolites of folate. This illustration also shows the close relationship of the folate cycle to the methionine remethylation cycl...
Relationship of the folate cycle to other biochemical pathways

The cyclic interconversions of the folate cycle are closely connected with thymidine synthesis (needed for DNA synthesis), trans-sulfuration, methionine synthesis (remethylation from homocysteine), and the methylation cycle (us...

Within the cytoplasm, folates from dietary sources are metabolized (reduced) by the enzyme dihydrofolate reductase to dihydrofolate (DHF).

Reaction schematic of the reduction of dihydrofolate to tetrahydrofolate catalyzed by dihydrofolate reductase

Legend: DHFR: dihydrofolate reductase; NADPH: nicotinamide adenine dinucleotide phosphate (the reduced form of NADP⁺). (Public domain.)

For this reaction, NADPH (from the pentose phosphate pathway) acts as an electron donor and gets oxidized to NADP+. DHF is further metabolized (reduced) by the same enzyme, dihydrofolate reductase, to tetrahydrofolate (THF). Again, another NADPH acts as an electron donor and gets oxidized to NADP+. Thus, this four-electron reduction of folic acid to THF proceeds in two chemical steps, both catalyzed by the same enzyme: dihydrofolate reductase.

All of the biological functions of folic acid are performed by THF and its methylated derivatives.

THF is (reversibly) metabolized by the enzyme serine hydroxymethyltransferase (SHMT) to N5, N10-methylene THF. In the process, a hydroxy group and a methyl group are transferred from the amino acid serine to form the amino acid glycine. Pyridoxal phosphate (the active form of vitamin B6) serves as a cofactor for this reaction, becoming pyridoxal.

N5, N10-methylene THF is a biochemical "hub" that can be utilized for many different purposes. For example, N5, N10-methylene THF can be either (1) recycled back into DHF (by thymidylate synthase); (2) reprocessed back into THF (by SHMT); (3) converted into 5-methyl THF (by MTHFR; driving the activated methyl cycle); or (4) converted to N5, N10-methenyl THF, then N10-formyl THF, and ultimately utilized for purine biosynthesis.

Reaction schematic of the reduction of 5,10-methylene-THF to 5-methyl-THF catalyzed by MTHFR

Legend: 5-methyl-THF: 5-methyl-tetrahydrofolate; 5,10-methylene-THF: 5,10-methylenetetrahydrofolate; MTHFR: methylenetetrahydrofolate reductase; NADPH: nicotinamide adenine dinucleotide phosphate (the reduced form of NADP⁺). (P...
Structural formula of 5,10-methenyltetrahydrofolate

(Public domain.)
Structural formula of 10-formyl-tetrahydrofolic acid

(Public domain.)

In the recycling of N5, N10-methenyl THF to DHF by thymidylate synthase, FADH2 gets oxidized to FAD, and deoxyuridine monophosphate (dUMP) gets converted to deoxythmydine monophosphate (dTMP). dTMP can then be utilized for DNA synthesis.

In the process of conversion of N5, N10-methenyl THF to 5-methyl THF by the enzyme methylenetetrahydrofolate reductase (MTHFR), a rate-limiting enzyme in the methyl cycle, the amino acid homocysteine is remethylated to the amino acid methionine.

Activated methyl cycle

The activated methyl cycle (or methionine cycle) involves: (1) the remethylation of homocysteine to methionine by the enzyme methionine synthase, which uses cobalamin (vitamin B12) as a cofactor; (2) the conversion of methionine to S-adenosyl methionine (SAM) by methionine adenosyltransferase (also known as S-adenosylmethionine synthetase); a multistep conversion of SAM to homocysteine, completing the cycle. SAM biosynthesis is the rate-limiting step of the methionine cycle.

Simplified schematic of the reaction of methionine synthase

This reaction serves as the interface of the folate cycle and the methionine remethylation cycle. The coenzyme, cobalamin (vitamin B12), utilizes cobalt to catalyze the transferring function in which the cobalt switches between...

S-adenosyl methionine (SAM) is a methyl donor for transmethylation and is also the propylamino donor in polyamine biosynthesis. In particular, SAM is a methyl donor in DNA methylation, a mechanism to control gene expression. SAM is also involved in gene transcription, cell proliferation, and production of secondary metabolites.

Purine biosynthesis

N5, N10-methylene THF is converted to N5, N10-methenyl THF by the enzyme methylene THF dehydrogenase (MTHFD). NADPH acts as an electron donor and gets oxidized to NADP+. N5, N10-methenyl THF is then converted to N10-formyl THF by the enzyme methenyl THF cyclohydrolase (MTHFC) (also called methenyl THF dehydrogenase), utilizing a water molecule in the process. Methenyl THF cyclohydrolase first oxidizes N5, N10-methylene THF to an iminium cation, which is then hydrolyzed to produce 5-formyl-THF and 10-formyl-THF.

Biotransformation of folic acid into folinic acids

R = para-aminobenzoate-glutamate. (Illustration created by "Boghog" on September 22, 2019. Creative Commons Attribution-Share Alike 4.0 International License.)

This series of reactions using the beta-carbon atom of serine as the carbon source provides the largest part of the one-carbon units available to the cell. (The beta carbon (β-carbon or Cβ) is the first carbon atom of an amino acid side chain, which, in a polypeptide, is attached to the polypeptide chain via the main‐chain alpha carbon atom.)

Two equivalents of N10-formyl THF are required in purine biosynthesis through the pentose phosphate pathway, where N10-formyl THF is a substrate for phospho-ribosyl-amino-imidazole-carboxamide formyltransferase. N10-formyl THF is also required for the formulation of methionyl-tRNA formyltransferase to give fMet-tRNA.

Causes of folate deficiency

Folate deficiency most frequently develops when there is insufficient folate in the diet, when there are increased folate requirements, when the body is unable to absorb dietary folate, or some combination of these.

Inadequate folate in the diet. Body stores for folic acid are limited to amounts sufficient for periods ranging from several weeks to 2 or 3 months on a folate-free diet.

Milk and breakfast cereal are fortified with folate. Natural dietary sources of folate include leafy green vegetables (eg, cabbage, kale, spring greens, lettuce, and spinach), other vegetables (eg, edemame or green soybeans, lentils, asparagus, peas, broccoli, brussels sprouts, chickpeas, kidney beans, sweet corn), tropical fruits (oranges, mangos, kiwis, avocados, papayas, bananas), fruit juices, and animal organs (eg, liver and kidneys).

The recommended daily allowance of dietary folate is 150 mcg/day for ages 1 to 3 years, 200 mcg/day for ages 4 to 8 years, 300 mcg/day for ages 9 to 13 years, 400 mcg/day for ages 13 years and older. Higher amounts are needed during pregnancy and lactation, but the recommended amounts vary somewhat by organization. The Institute of Medicine has set recommended daily allowances of 600 mcg/day for pregnancy and 500 mcg/day for lactation (76). The US Public Health Service and its subsidiary the Centers for Disease Control recommend that all women of reproductive age should get 400 mcg of folic acid each day, in addition to consuming food with folate from a varied diet, to help prevent neural tube defects (37). The US Preventive Services Task Force recommends that all women who are planning or capable of pregnancy take a daily supplement containing 0.4 to 0.8 mg (400 to 800 µg) of folic acid (150; 154). The critical period for supplementation starts at least one month before conception and continues through the first 2 to 3 months of pregnancy (ie, when the neural tube closes). However, because half of all pregnancies in the United States are unplanned, clinicians should advise all women who are capable of pregnancy to take daily folic acid supplements (150; 154).

A much higher amount of supplementation, 4000 mcg/day (4 mg/day), is recommended during pregnancy for women with a high risk of delivering a child with a neural tube defect (NTD), specifically women who have had an NTD-affected pregnancy (36; 37). High-dose supplementation may also be considered for women with a family history of neural tube defects and for women with concurrent use of medications that increase the risk of neural tube defects (eg, some anticonvulsants).

Those at risk for dietary folate deficiency include people who have a history of alcoholism, substance abuse, or severe mental illness, the elderly, those with other reasons for poor dietary intake (eg, anorexia due to malignancies or AIDS), and some individuals on fringe diets.

Inability to absorb folate (acquired). Inability to absorb folate may develop in various intestinal diseases and conditions (eg, celiac disease, tropical sprue, post-gastrectomy, short-bowel syndrome (short-gut syndrome), postinfective malabsorption) in which uptake of multiple nutrients may be impaired (75; 74; 102; 147; 67; 16; 21; 51; 90). Folate deficiency is often seen in individuals with alcoholism, reflecting a combination of poor diet, intestinal malabsorption (partly resulting from alcohol-inhibited expression of the reduced folate carrier), reduced liver uptake and storage, and reduced renal conservation of circulating folate (ie, with resulting increased urinary folate excretion) (68; 90; 101).

Antifolate medications. Antifolate medications disrupt the metabolic pathways that require 1-carbon moieties supplied by folate. Antifolates disturb folate-homocysteine metabolism through a variety of mechanisms, including (1) inhibiting enzymes of the folate cycle, such as dihydrofolate reductase (DHFR) and methylenetetrahydrofolate reductase (MTHFR); (2) impairing folate absorption; (3) increasing elimination of folate; and (4) increasing turnover of folate, eg, by inducing liver enzymes (153). Antifolates can produce hematologic and neurologic consequences, like folate deficiency acquired in some other manner (109).

Methotrexate, for example, is a folate antagonist that acts on multiple enzymes, including DHFR, MTHFR, GARFT (glycinamide ribonucleotide transformylase), AICARFT (aminoimidazole-4-carboxamide ribonucleotide formyltransferase), and TYMS (thymidylate synthetase). Methotrexate has a close chemical structural similarity to folic acid, so it is not surprising that it can interfere with enzymes that act on or utilize metabolites of folic acid.

Chemical structure of folic acid (top) compared to methotrexate (bottom)

(Public domain.)

Methotrexate is actually a prodrug, which is activated intracellularly to form methotrexate polyglutamates through sequential addition of glutamic acid residues by the enzyme folylpolyglutamate synthase (FPGS), an enzyme that is essential for folate homeostasis and the survival of proliferating cells; FPGS normally functions to establish and maintain both cytosolic and mitochondrial folylpolyglutamate concentrations by catalyzing the ATP-dependent addition of glutamate moieties to folate and folate derivatives. This polyglutamation of methotrexate promotes its retention intracellularly, resulting in enhanced inhibitory effects against target enzymes. Within the cell, methotrexate polyglutamates bind to and inhibit dihydrofolate reductase and other folate pathway enzymes required for purine and pyrimidine synthesis, thereby providing anti-inflammatory effects.

Because of its folic acid antagonism, methotrexate can produce hematologic manifestations of megaloblastic anemia, including hypersegmented neutrophils (109). Treatment with methotrexate typically necessitates "leucovorin rescue," which uses the folate derivative leucovorin (folinic acid) in lieu of folic acid because folinic acid does not need to undergo reduction by the enzyme dihydrofolate reductase for utilization in one-carbon transfer reactions (eg, in DNA synthesis).

Structural formula of folinic acid (leucovorin)

(Public domain.)

Table 1. Medications that Interfere with Folate-Homocysteine–Methionine Pathway

Drug Class	Drug	DHFR Inhibitor	Inhibitor of Other Enzymes/Transporters
Antiepileptic	Lamotrigine	+
	Phenytoin		MTHFR, MS
	Valproic acid		MTHFR, FTCD
Oncologic	Aminopterin	+
	Edatrexate	+
	Methotrexate	+	MTHFR, GARFT, AICARFT, TYMS
	Pemetrexed	+	GARFT, AICARFT, TYMS
	Piritrexim	+
	Pralatrexate	+
	Talotrexin	+
	Trimetrexate	+
	Raltitrexed		TS
Other	Pyrimethamine	+
	Sulfasalazine	+	MTHFR, SHMT, RFC
	Triamterene	+
Legend: DHFR - dihydrofolate reductase; FTCD - formimidoyltransferase cyclodeaminase (or formiminotransferase cyclodeaminase); GARFT - glycinamide ribonucleotide formyltransferase; MS – methionine synthase; MTHFR - methylenetetrahydrofolate reductase; RFC – reduced folate carrier; SHMT - serine hydroxymethyltransferase; TS - thymidylate synthase

Table 2. Medications that Interfere with Folate Absorption, Utilization, or Elimination

Drug Class	Drug	Decreases Absorption	Increases Metabolism	Increases Elimination
Antiepileptic	Carbamazepine	+	+
	Gabapentin	+
	Oxcarbazine	+
	Phenobarbital	+
	Phenytoin	+
	Primidone	+
	Valproic acid	+
Other	Cholestyramine	+
	Loop diuretics (eg, furosemide)			+
	K+-sparing diuretics (eg, amiloride)			+
	Triamterene	+
	Oral contraceptives (eg, ethinyl estradiol)	+	+	+
	Methotrexate			+
Legend: K+-sparing = potassium-sparing

Increased folate requirements. Folate deficiency may be seen in individuals with increased folate requirements (eg, pregnant women, growing children, individuals on hemodialysis, and individuals with chronic hemolytic anemia, exfoliative skin conditions, leukemia, and lymphoma).

Genetic defects in folate uptake and transport. A small number of individuals have hereditary folate malabsorption and develop folate deficiency during the first months of life as a result of mutations in the SLC46A1 (solute carrier family 46 member 1) gene, located on chromosome 17q11.2, which encodes the proton-coupled folate transporter (PCFT) (116; 117; 43; 140; 115; 98; 31; 119; 162; 170; 129; 130; 169; 84; 155; 01; 50; 148; 159; 168). The proton-coupled folate transporter is required for absorption of dietary folate across the apical brush-border membrane of the proximal small intestine. Affected individuals have very low CSF and serum folate levels. This disorder is inherited as an autosomal recessive trait and is characterized clinically by megaloblastic anemia, hypogammaglobulinemia, oral ulcers, and progressive neurologic deterioration in the absence of therapy (59; 136). Affected individuals are normal at birth but within a few months, if untreated, develop anemia, hypogammaglobulinemia with immune deficiency and infections, and progressive neurologic dysfunction (developmental delay, ataxia, seizures, leukoencephalopathy, and neuropathy) (169; 03; 86).

In addition to transport mediated by solute carriers, folate is also transported by folate receptor-mediated endocytosis involving two genetically distinct proteins, folate receptor 1 (folate receptor alpha or FRα encoded by the FOLR1 gene) and folate receptor 2 (FRβ encoded by the FOLR2 gene). FRα is needed for transport of folate across the blood-brain barrier at the choroid plexus. Several families have been described with an autosomal recessive disorder due to loss-of-function mutations in the FOLR1 gene (OMIM 613068) (33; 139; 63; 169; 45). Like infants affected with hereditary folate malabsorption, these children have very low CSF folate levels (5MTHF level < 5 nmol/l), but unlike those affected with hereditary folate malabsorption, they have normal intestinal folate absorption, so their serum folate levels are normal (169). Neurologic manifestations develop later than in hereditary folate malabsorption, typically several years after birth rather than several months after birth in hereditary folate malabsorption (169). If untreated, affected children begin to regress in the second year of life and develop ataxia and refractory myoclonic epilepsy (45). Treatment with 5-formyltetrahydrofolate (folinic acid; leucovorin) can result in clinical improvement, but intravenous administration high-dose 5-formyltetrahydrofolate (folinic acid; leucovorin) may be necessary to control seizures and stop neurologic regression (45).

Folate receptor alpha (FRα) autoimmunity with low CSF N(5)-methyl-tetrahydrofolate (MTHF) levels has also been suggested to underlie cases of autism and schizophrenia (47; 121). In FRα autoimmunity syndromes, abnormal behavior may fluctuate with fluctuating FRα antibody titers and associated changes in CSF folate, tetrahydrobiopterin, and neurotransmitter metabolites (47; 121).

Consequences of folate deficiency

Megaloblastic anemia. In folate deficiency, impaired nucleotide synthesis is likely responsible for the megaloblastic anemia, which is characterized by abnormal DNA synthesis in rapidly proliferating tissues. DNA synthesis abnormalities cause ineffective erythropoiesis resulting from intramedullary apoptosis of hematopoietic cell precursors. The bone marrow produces unusually large, structurally abnormal, immature red blood cells (megaloblasts) that are released as macrocytes into the peripheral blood.

Macrocytes in peripheral blood smear from a patient with megaloblastic anemia

Macrocytosis is the presence of red cells that are larger than normal (macrocytes) in peripheral blood. They occur in peripheral blood as a result of premature release from the marrow. They are commonly seen in pregnant women, ...

Hypersegmented neutrophils are detectable in a peripheral blood smear. Poikilocytosis and anisocytosis are common due to ineffective erythropoiesis.

Hypersegmented neutrophil in peripheral blood smear from a patient with megaloblastic anemia

(Source: Photomicrograph by Ed Uthman, Houston, Texas on January 21, 2013. Creative Commons Attribution 2.0 Generic license.)

Hyperhomocysteinemia. Decreased methionine synthase activity results in accumulation of its substrate homocysteine in blood and urine (hyperhomocysteinemia and homocysteinuria, respectively). Hyperhomocysteinemia is an important risk factor for vascular disease, including stroke, independent of long-recognized factors such as hypertension, diabetes mellitus, smoking, and hyperlipidemia.

Inhibition of transmethylation reactions as well as decreased concentrations of methionine and its product, S-adenosylmethionine, may cause the neurologic consequences of folate deficiency.

Neural tube defects. Folate deficiency is known to contribute to neural tube and neural crest defects, but the reasons for this developmental tissue specificity and the molecular mechanisms involved in those abnormalities are still poorly understood, although they are beginning to be elucidated.

Folate transporters (SLC19A1, SLC46A1, SLC25A32, and FOLH1) and folate receptors (FOLR1, FOLR2, and FOLR3) transport folate from maternal intestinal lumen to the developing embryo (53); loss of function variants in genes involved in folate transport have been identified in subjects with myelomeningocele (53).

Disturbed epigenetic modifications, including microRNA (miRNA) regulation, have been linked to the pathogenesis of neural tube defects in women with folate deficiency (158); a microRNA is a small non-coding RNA molecule (typically containing about 22 nucleotides) that functions in RNA silencing and post-transcriptional regulation of gene expression.

Two of the main folate transporters, FolR1 (adult folate receptor, or folate-binding protein) and Rfc1 (replication factor C subunit 1), are robustly expressed in developing neural tube and neural crest, and together they control the availability of methyl donor groups for histone and DNA methylation (04). Loss of folate transporters or pharmacological inhibition of folate transport/metabolism alters neural crest precursors by affecting the repression of the SOX2 gene in the dorsal neural tube (04); SOX2 (SRY-box 2, sex determining region Y-box 2) is a transcription factor that is essential for maintaining the pluripotency of undifferentiated embryonic stem cells. The reduced number of neural crest precursors leads to orofacial defects by affecting maxillary development. Lack of Sox2 repression caused by folate deficiency results from a DNA methylation defect on the Sox2 locus at the dorsal neural tube. Folinic acid supplementation can rescue the observed defects. Thus, we identify a molecular mechanism that is disrupted by folate deficiency, leading to the neural crest development defects. Folate, thus, serves as a source of the methyl groups that are needed to establish the correct epigenetic program during neural and neural crest fate-restriction.

Members of the fibroblast growth factor signaling pathway function early in embryonic development and during organogenesis to maintain and mediate the growth, differentiation, survival, and patterning of progenitor cells (112). The fibroblast growth factor family is comprised of 18 secreted proteins that interact with four signaling tyrosine kinase fibroblast growth factor receptors. Inappropriate expression of fibroblast growth factor and improper activation of fibroblast growth factor receptors are associated with various pathologic conditions, unregulated cell growth, and tumorigenesis (145). Abnormalities in the fibroblast growth factor signaling pathway have been implicated in human folic-acid-insufficiency encephalocele (39). Aberrant fibroblast growth factor signaling pathway activity was found in fetal brain dysplasia in mice with maternal folate-deficient diets. In knockout mice and cell models, the effects of folate deficiency are apparently mediated by hypermethylation causing low expression of TBXT (39), which encodes Brachyury, a protein transcription factor within the T-box family of genes (39).

Folate deficiency activates Wnt/β-catenin signaling by upregulating a chorion-specific transcription factor Gcm1, which ultimately causes aberrant vertebrate neural development (92). In early neural development, aberrant activation in Wnt/β-catenin pathway causes defective anteroposterior patterning, which results in neural tube closure defects. In neural-tube defect mouse models and brain samples from human low-folate neural tube defects, Gcm1 and Wnt/β-catenin targeted genes related to neural tube closure are specifically overexpressed (92).

Down syndrome. Mothers with polymorphisms in folate-homocysteine pathway genes are more likely to have children with Down syndrome, a genotypic risk that can potentially be mitigated by periconceptional nutritional supplementation (78; 141).

Fragile X syndrome. Expansion of a CGG trinucleotide repeat sequence in the FRAXA locus associated with fragile X syndrome exhibits fragility in response to folate deficiency or other forms of "folate stress" (24). Folate stress, by disturbing the replication program within the pathologically expanded repeats within FRAXA, produces a marked increase in missegregation of FRAXA coupled with formation of single-stranded DNA bridges in anaphase and micronuclei that contain the FRAXA locus (24).

Epidemiology

	• The prevalence of folate deficiency has since dropped from between 2% and 5% to around 1% or less in countries with folate supplementation.
	• The prevalence of folate deficiency remains higher in underdeveloped countries and also in developed countries that have not adopted folate supplementation.
	• Even in countries with folate supplementation, certain population groups have a significant frequency of folate deficiency, including the elderly, pregnant woman, individuals with alcohol use disorders, individuals with malabsorption, indigenous rural and urban poor populations, and some minority groups.
	• Food fortification with folic acid reduces the inadequacy of dietary folate intake but is insufficient to ensure safe levels for pregnant women.
	• Prenatal maternal folate deficiency is associated with reduced prenatal brain growth and psychological problems in offspring.
	• Folate insufficiency in early pregnancy has a long-lasting, global effect on brain development and is associated with poorer cognitive performance.
	• Countries with mandatory folic acid fortification policies have experienced marked reductions in neural tube defects, whereas, in contrast, measures to prevent neural tube defects in European countries have been largely ineffective because of poor compliance of women with folic acid supplementation before and in early pregnancy.
	• Higher maternal plasma folate levels are associated with lower risk of preterm birth.
	• Folate deficiency in elderly adults is associated with worse cognitive performances, even after correction for sex, age, and years of education, with a more severe cognitive impairment when hyperhomocysteinemia is present.

Folate deficiency, defined by measurement of serum or erythrocyte folate concentrations, occurred in 2% to 5% of individuals tested in the United States before 1998. In 1998, fortification of cereal grains was started in the United States, Canada, and other countries. The prevalence of folate deficiency has since dropped to around 1% or less in countries with folate supplementation (13; 108; 61; 28; 64; 134).

Even in countries with folate supplementation, certain population groups have a significant frequency of folate deficiency, including the elderly, pregnant woman, individuals with alcohol and substance use disorders, individuals with malabsorption, indigenous rural and urban poor populations, immigrants, some minority groups, and subjects with malabsorption (eg, inflammatory bowel disease) (15; 10; 17; 79; 123; 125; 42; 128; 73; 93; 26). Consequently, folate deficiency is seen at a higher frequency in urban "safety net" hospitals than at private hospitals. At one "safety net" hospital in Boston in 2018, 5.5% of 1368 patients tested met criteria for folate deficiency (73). Overall, 87% of these patients were anemic, 17% had macrocytic anemia, and 42% were diagnosed with malnutrition. Frequent psychosocial factors contributing to adverse health outcomes in folate-deficient patients included birth outside of the United States, homelessness, and alcohol use disorder.

Pregnant women and infants. In the randomized controlled NiPPeR trial, 1729 women (from the United Kingdom, Singapore, and New Zealand) aged 18 to 38 years and planning conception were randomized to receive a standard vitamin supplement or an enhanced vitamin supplement starting in preconception and continued throughout pregnancy (62). At recruitment, 29% had marginal or low plasma folate status (< 13.6 nmol/L). After 1 month of supplementation, plasma concentrations of supplement components were substantially higher among participants in the intervention group than those in the control group.

In a metaanalysis of folate deficiency among women of reproductive age in Ethiopia, the pooled prevalence of folate deficiency was estimated to be 21% (58).

In a Norwegian study of pregnant women, a high proportion had folate deficiency at the end of pregnancy: at gestational weeks 18 and 36, respectively, 3.7% and 30% of pregnant women had folate concentrations less than 10 nmol/L (26).

In the Norwegian study, none of the infants had folate concentrations <10 nmol/L even though a high proportion of pregnant women had folate deficiency at the end of pregnancy (26). Maternal folate status during pregnancy was not associated with infants’ folate status at ages 3 and 6 months (26). Other studies have similarly found no association between maternal folate status during pregnancy and infant folate status at age 6 months (70). Folate concentration in human milk is relatively stable and independent of the maternal folate status (06), providing protection against low folate in infants even when maternal folate is low (05).

Mortality. Lower serum folate concentrations (and resultant higher serum homocysteine) are associated with an increased risk of all-cause, cardiovascular disease, and cancer-related mortality in Korean adults (137).

Dementia. Folate deficiency is associated with incident dementia, but available studies cannot adequately exclude so-called "reverse causation" (ie, that dementia leads to folate deficiency), although it is also possible that causation may work in both directions simultaneously. A prospective cohort of 27,188 people aged 60 to 75 years without preexisting dementia had serum concentrations of folate measured at study inception, after which subjects were followed for incident dementia or all-cause mortality (126). Serum folate levels were dichotomized as deficient (less than 4.4 ng/mL) or not deficient. Serum folate deficiency was significantly associated with higher risks of dementia (hazard ratio = 1.68) and all-cause mortality (hazard ratio = 2.98). An attempt was made to assess reverse causation, by stratifying the duration of follow-up; based on this, the authors concluded that the evidence for reverse causation were moderate for dementia and mild for all-cause mortality.

Folate deficiency in elderly adults is associated with worse cognitive performances, even after correction for sex, age, and years of education, with a more severe cognitive impairment when hyperhomocysteinemia is present (18). In a prospective study on the older Chinese population without folic acid fortification, lower folate concentrations, independently of APOE genotype, were associated with increased risk of mild cognitive impairment among elderly Chinese people, a population with relatively low folate intake (55).

Peripheral neuropathy. Folate deficiency and insufficiency were significantly associated with a greater risk of peripheral neuropathy among younger patients (younger than 40 years of age), but no such association was evident among those among those aged 41 to 70 years (144).

Adverse pregnancy outcomes. Food fortification with folic acid reduces the inadequacy of dietary folate intake but is insufficient to ensure safe levels for pregnant women (123). A decline in neural tube defects was observed for all three of the racial and ethnic groups (Hispanic; White, non-Hispanic; Black, non-Hispanic) examined between the prefortification and postfortification periods in the United States (163).

Prevalence of neural tube defects (anencephaly and spina bifida) before and after mandatory folic acid fortification

Prevalence by maternal race and ethnicity: 19 population-based birth defect surveillance programs, United States, 1995-2011. Contributing programs were based in Arkansas, Arizona, California, Colorado, Georgia, Illinois, Iowa, ...

Overall, a 28% reduction in prevalence was observed for anencephaly and spina bifida (163). The birth prevalence of neural tube defects during the postfortification period has remained relatively stable since the initial reductions observed during 1999 to 2000, immediately after mandatory folic acid fortification in the United States. Approximately 1,300 neural tube defect-affected births were averted annually during the postfortification period (163). Hispanics consistently have had a higher prevalence of neural tube defects compared with the other racial and ethnic groups, whereas non-Hispanic blacks generally have had the lowest prevalence (163).

Folate deficiency and genetic polymorphisms in one-carbon metabolism are associated with a higher risk of neural tube defects in offspring (158; 30). In particular, mothers carrying polymorphisms in the genes for methylenetetrahydrofolate dehydrogenase, methylenetetrahydrofolate reductase, and 5-methyltetrahydrofolate-homocysteine methyltransferase reductase have been associated with higher risks of neural tube defects in their offspring (30).

A retrospective cohort study in Turkey found that low maternal folate status coupled with B12 deficiency was strongly associated with neural tube defects (14).

Prenatal maternal folate deficiency is also associated with reduced prenatal brain growth and psychological problems in offspring. Folate insufficiency in early pregnancy has a long-lasting, global effect on brain development and is associated with poorer cognitive performance (12).

Countries with mandatory folic acid fortification policies have experienced marked reductions in neural tube defects, whereas, in contrast, measures to prevent neural tube defects in European countries have been largely ineffective because of poor compliance of women with folic acid supplementation before and in early pregnancy (100).

Despite some heterogeneity in study results, most well-conducted studies with sufficient subjects and published in 2000 or later have reported that higher homocysteine and lower folate concentrations in early pregnancy are significantly associated with lower placental weight and birthweight, and a higher risk of adverse pregnancy outcomes. Furthermore, vitamin supplementation in early pregnancy resulted in lower frequencies of preeclampsia and adverse pregnancy outcomes.

	• In a case-control study in Zimbabwe among 171 cases with preeclampsia or eclampsia and 185 normotensive control subjects, women with plasma folate concentrations less than 5.7 nmol/L experienced a 10.4-fold increased risk of preeclampsia (120).
	• In a Norwegian study of 14,492 pregnancies reported to the Medical Birth Registry of Norway from 1967 to 1996, elevated total homocysteine concentration was associated with common pregnancy complications and adverse pregnancy outcomes (156).
	• The Pregnancy Exposures and Preeclampsia Prevention Study (1997 to 2001) found lower rates of severe preterm births and extreme small-for-gestational-age births in women who report periconceptional vitamin use (35).
	• In a prospective cohort study of 2951 pregnant women between October 2002 to December 2005 in Ottawa, Canada, supplementation of multivitamins containing folic acid in the second trimester is associated with reduced risk of preeclampsia: specifically, supplementation of multivitamins containing folic acid was associated with significantly decreased plasma homocysteine (on average 0.39 micromol/L), and reduced risk of preeclampsia (adjusted odds ratio 0.37) (161).
	• In a population-based birth cohort study in Rotterdam, the Netherlands, higher homocysteine and lower folate concentrations in early pregnancy were significantly associated with lower placental weight and birthweight, and higher risk of adverse pregnancy outcomes (22).
	• In a retrospective case-control study of 400 primiparous women conducted in Australia, maternal RBC folate concentration in early pregnancy was associated with small-for-gestational-age infants and preterm birth, but not with preeclampsia (56).
	• A prospective observational study of 137 subjects identified prior to the 20th week of gestation in Australia, low maternal RBC folate and high homocysteine values in mid pregnancy were associated with subsequent reduced fetal growth (57).
	• In a general cohort of pregnant women from Quebec, Canada, benefiting from a national policy of folic acid food fortification combined with a high adherence to folic acid supplementation, serum folate levels were high and did not differ between women who developed a hypertensive disorder of pregnancy and women who remained normotensive (146).
	• In a birth cohort study conducted in 2010 to 2012 in Lanzhou, China, among a total of 10,041 pregnant women without chronic hypertension or gestational hypertension, folic acid supplementation and higher dietary folate intake during pregnancy significantly reduced the risk of preeclampsia (160).
	• In the Environments for Healthy Living Project of 2261 pregnancies in Australia, maternal supplementation with multivitamins in the first trimester of pregnancy results in a 55% reduction in pre-eclampsia risk in overweight women (BMI: 25-29.9) and a 62% risk reduction in obese women (BMI: ≥30) (151).
	• Higher maternal plasma folate levels are associated with lower risk of preterm birth (111). In addition, compared with less frequent use, multivitamin supplement intake at least three to five times per week throughout pregnancy is associated with a reduced risk of preterm birth (111).
	• In the Sichuan Homocysteine study in China—a multicenter, retrospective, case-control study involved 563 pregnant women with adverse pregnancy outcomes and 600 controls—higher homocysteine concentration and lower folate level during early pregnancy were associated with adverse pregnancy outcomes (94).
	• In a case-control study conducted in Barcelona, Spain, pregnant women with hyperhomocysteinemia had a 7.7-fold risk for preeclampsia compared with normal controls (95).
	• In a study of 2584 mothers enrolled within 3 days postpartum from a high-risk multiethnic U.S. population (Boston), preeclampsia disorders, but not gestational hypertension, were associated with lower folate and higher homocysteine levels postpartum, especially among Black mothers (110).
	• In a high-risk birth cohort, low maternal folate status was associated with increased risk of placental maternal vascular malperfusion (40).

In addition, certain polymorphisms in MTHFR, the gene coding for methylenetetrahydrofolate reductase, have been associated with increased risks for preeclampsia.

	• In a metaanalysis involving collectively 7398 cases and 11,230 controls, the MTHFR C677T genotype was associated with increased risk for preeclampsia, especially among Asians and Caucasians (165).
	• In a matched (for age and parity) case-control study in Sudan, the MTHFR C677T variation was significantly more frequent in women with preeclampsia (16%) than in healthy pregnant women (2%) (OR = 10.1) (02).
	• In a population of pregnant women in Lagos, Nigeria, MTHFR C677T polymorphisms were associated with preeclampsia (113).

Prevention

	• Good sources of folate include green leafy vegetables, beans, nuts, dairy products, and meat (particularly liver); in the United States and in other countries where cereal grains are supplemented with folic acid, these are also excellent folate sources.
	• In patients who have had bariatric surgery, periodic surveillance should be performed for commonly deficient micronutrients, including folate.
	• Pregnant women have an increased requirement for folate.
	• Folate supplementation in pregnant women during the periconceptional period reduces the occurrence of neural tube defects.

Folate is a vitamin, and individuals need to consume adequate amounts to avoid the consequences of deficiency. The recommended daily allowance (RDA) of folate is 400 µg/day for adults; the RDAs for pregnant and lactating women are 600 µg/day and 500 µg/day, respectively. The RDA for children 1 to 3 years of age is 150 µg/day, 200 µg/day for children 4 to 8 years old, and 300 µg/day for children 9 to 13 years old. Good sources of folate include green leafy vegetables, beans, nuts, dairy products, and meat (particularly liver); in the United States and in other countries where cereal grains are supplemented with folic acid, these are also excellent folate sources.

In patients who have had bariatric surgery, periodic surveillance should be performed for commonly deficient micronutrients, including folate (B9), as well as thiamin (B1), cobalamin (B12), iron, and vitamin D (152; 20); following Roux-en-Y gastric bypass, serum levels of copper and zinc should also be monitored (152).

Some individuals with folate concentrations within the reference range may be functionally folate deficient. Pregnant women have an increased requirement for folate; in particular, folate supplementation in pregnant women during the periconceptional period reduces the occurrence of neural tube defects. Closure of the neural tube occurs early in fetal development, before many women are aware that they are pregnant, leading to the recommendation that all woman of childbearing age should receive folate supplementation (11). Daily supplementation with folic acid of 400 μg/day avoids the risk of folate deficiency in most women (11), although women with low red blood cell-folate are unlikely to achieve desirable levels within 4 to 8 weeks unless they receive 800 µg/day (107). Because folic acid must be converted to its active form, tetrahydrofolate, or its main circulating form, 5-methyltetrahydrofolate (5-MTHF), some have advocated using 5-MTHF as a supplement, especially during pregnancy (52), whereas others have recommended synthetic analogs that also present advantages over folic acid supplementation (71). In the United States, Canada, and several other countries, cereal grains are now fortified with folic acid; this supplementation has resulted in decreased occurrence of neural tube defects (23).

Individuals with certain genetic backgrounds may be more sensitive to the consequences of reduced folate concentrations (90). Individuals homozygous for the T allele of the common c.677C>T polymorphism in the MTHFR gene, which encodes the folate metabolic enzyme methylenetetrahydrofolate reductase (MTHFR), develop hyperhomocysteinemia when serum folate concentration is in the low normal range; hyperhomocysteinemia is not present in TT individuals with serum folate concentrations above the median value (77). The prevalence of the TT genotype varies between 8% and 14% in white North American populations; the prevalence is similar in northern Europe and higher in southern Europe and in the Mexican and other Hispanic populations. The prevalence is low (less than 2%) in populations of African origin (41; 25). The T-allele of the genetic polymorphism MTHFR677C>T may increase the risk of developing schizophrenia and may worsen functional capacity in such patients (171).

In cases of hereditary folate malabsorption, it is critical that the correct diagnosis is made quickly, before neurologic changes associated with the condition become irreversible.

Excess folate intake from prevention efforts has raised concerns regarding the promotion of folate-sensitive cancers, including colorectal cancer (105; 135).

Diagnostic workup

	• Identification of folate deficiency depends on measurement of the serum or erythrocyte folate concentration.
	• A variety of drugs interfere with folate absorption or metabolism and consequently produce unwanted side effects.
	• Hyperhomocysteinemia and homocystinuria, with decreased or low normal serum methionine concentration, occur in folate deficiency as the result of decreased methionine synthase activity.
	• Supplementation with oral folic acid results in correction of hematologic, biochemical, and neurologic signs of folate deficiency.
	• Rule out vitamin B12 deficiency before starting folic acid therapy.

Folate deficiency is typically accompanied by a macrocytic anemia with an mean corpuscular volume greater than 100 fL and associated megaloblastic changes on peripheral blood smear, including macrocytes, ovalocytes, and hypersegmented neutrophils (more than five lobes) (138). Lactate dehydrogenase is also elevated. Leukopenia and thrombocytopenia may also develop, resulting in pancytopenia (106). Although circulating erythrocytes are usually macrocytic, the presence of concurrent iron deficiency can mask macrocytosis.

The bone marrow (if assessed) is hypercellular with megaloblastic maturation of erythroid precursors that demonstrate apparent asynchrony between a large, immature-looking nucleus and a normally maturing cytoplasm. Histologically, the megaloblastosis caused by folic acid deficiency cannot be differentiated from that observed with vitamin B-12 deficiency.

Identification of folate deficiency depends on measurement of the serum or erythrocyte folate concentration. Values vary between different technologies and different laboratories (34). Serum folate concentrations tend to be labile and may reflect transient dietary variations whereas erythrocyte folate assays are often unreliable for technical analytic reasons (85; 135). Because the folate content of erythrocytes is fixed during erythropoiesis, erythrocyte folate concentrations are indicative of folate status over the preceding 4-month period (135).

A careful review of medications is indicated in patients with folate deficiency or suspected deficiency. A variety of drugs interfere with folate absorption or metabolism and consequently produce unwanted side effects, including antiepileptic drugs (valproic acid, lamotrigine, carbamazepine, Oxcarbazepine, phenytoin, gabapentin, phenobarbital, primidone), oral contraceptives, antimicrobial drugs (trimethoprim, pyrimethamine), cholestyramine, triamterene, and sulfasalazine (153). Other drugs that interfere with folate metabolism are employed therapeutically for various oncological indications, including aminopterin, edatrexate, methotrexate, pemetrexed, piritrexim, pralatrexate, and talotrexin (153).

Note that methotrexate and 5-formyltetrahydrofolate (also known as folinic acid in Britain and leucovorin in the United States) interfere with measurement of folate. Macrocytic anemia and megaloblastic bone marrow are frequently present; these are also seen in vitamin B12 deficiency, and macrocytosis may be absent when folate deficiency occurs in the presence of deficiency of other nutrients, such as iron.

Hyperhomocysteinemia and homocystinuria, with decreased or low normal serum methionine concentration, occur in folate deficiency as the result of decreased methionine synthase activity. These also occur in vitamin B12 deficiency, where they are accompanied by methylmalonic acidemia and aciduria, which are absent in folate deficiency.

Supplementation with oral folic acid results in correction of hematologic, biochemical, and neurologic signs of folate deficiency. The hematologic response can occur within 72 hours, and a positive hematologic response can be considered a confirmatory diagnostic test.

It is important to distinguish between folate and vitamin B12 deficiency. High doses of folic acid (1 mg per day or greater) can result in temporary resolution of hematologic findings in vitamin B12-deficient individuals, but do not affect neurologic consequences, which can progress and become irreversible (90). Therefore, rule out vitamin B12 deficiency before starting folic acid therapy.

Decreased CSF folate concentrations in the presence of normal serum and erythrocyte concentrations are seen in individuals with cerebral folate deficiency caused by decreased function of folate receptor alpha, either due to autoantibodies against folate receptor alpha or mutations at the FOLR1 gene.

Management

	• Treatment of dietary folate deficiency depends on replenishing the body’s folate stores and then ensuring that there is adequate folate in the diet (or in supplements) to avoid recurrence.
	• In cases of folate deficiency due to inadequate dietary intake or malabsorption, daily 1 mg doses of oral folic acid are usually sufficient.

Treatment of dietary folate deficiency depends on replenishing the body’s folate stores and then ensuring that there is adequate folate in the diet (or in supplements) to avoid recurrence. In cases of folate deficiency due to inadequate dietary intake or malabsorption, daily 1 mg doses of oral folic acid are usually sufficient, although higher doses have been advocated in the past. Treatment is continued for 3 to 4 weeks, and then the patient is placed on maintenance therapy with 0.2 mg daily (unless there are extenuating circumstances, such as pregnancy, women of reproductive age, women who have previously had a pregnancy complicated by a neural tube defect, or identified genetic disorders related to folate malabsorption or metabolism).

Treatment of hereditary folate malabsorption due to mutations at SLC46A1 is complicated because the proton-coupled folate transporter supports transport of folates across both the intestinal epithelia and the blood-brain barrier at the choroid plexus. Treatment with oral folic acid may be sufficient to correct the hematologic findings but insufficient to raise CSF folate concentration. Successful treatment has involved parenteral administration of a reduced form of folate [5-formyltetrahydrofolate (also known as folinic acid in Britain and leucovorin in the United States) or 5-methyltetrahydrofolate]; these forms cross the blood-brain barrier more readily than does folic acid (81). It is of critical importance to monitor CSF folate concentration to ensure that it remains at or above 100 nM. Typically, therapy starts with 1.5 or 5 mg IM daily; dosage is then increased, if necessary, until adequate CSF folate concentration is attained and maintained.

Cerebral folate transporter deficiency caused by loss-of-function FOLR1 mutations has also been effectively treated with 5-formyltetrahydrofolate (folinic acid; leucovorin); intravenous administration of high-dose 5-formyltetrahydrofolate may be necessary to control seizures and stop neurologic regression (45).

Outcomes

Dietary folate deficiency and acquired folate malabsorption respond well to supplementation with 1 mg oral folic acid daily, with resolution of hematologic, neurologic, and biochemical findings.

In an uncontrolled trial of elderly patients with folate deficiency and cognitive impairment, folate supplementation ameliorated cognitive impairment, at least for a short period (69).

In hereditary folate malabsorption, transport of folate is impaired at both the intestinal epithelium and the blood-brain barrier at the choroid plexus. Oral folate can readily correct the hematological and biochemical findings while CSF folate concentration remains low and neurologic findings continue to progress. This disorder needs to be treated with parenteral reduced folate [5-formyltetrahydrofolate (also known as folinic acid in Britain and leucovorin in the United States) or 5-methyltetrahydrofolate] to ensure that neurologic problems are corrected.

Special considerations

Pregnancy

Folate requirements are increased during pregnancy due to requirements of the fetus and, possibly, due to increased folate catabolism (142; 90). Folate deficiency is associated with an increase in spontaneous abortions and congenital malformations, particularly neural tube defects and congenital heart disease (44; 90). Folate supplementation early in pregnancy, at the time of closure of the neural tube, reduces the incidence of fetal neural tube defects (90). Folate should be provided preconceptionally because many women are not aware that they are pregnant at the time of neural tube closure (11). Consequently, all women of reproductive age should take 400 to 800 mcg of folic acid each day. Higher doses of folic acid are recommended for women with a history of a child with a neural tube defect from a prior pregnancy, those with certain folate-enzyme genotypes or malabsorption disorders, and those who take antifolate medications or smoke (90; 83).

In 1991, a large, multicenter randomized clinical trial demonstrated that supplementation with 4 mg of folic acid beginning prior to conception decreased the risk of recurrent neural tube defects by 71% (103). These findings have since been considered definitive in supporting high-dose folic acid supplementation among women at increased risk for pregnancies complicated by a neural tube defect. The MRC’s rationale for selecting this high dose was based on prior findings and concern that inconclusive findings with a lower-dose trial might preclude any opportunity to repeat the study with a higher dose (91). In 1991, in response to the findings of the MRC study, the Centers for Disease Control and Prevention recommended high-dose folic acid supplementation (4 mg per day) for women who previously had an infant or fetus with spina bifida, anencephaly, or encephalocele, with supplementation to begin at the time such women plan to become pregnant (36). The CDC recommended that women should take the supplement from at least 4 weeks before conception through the first 3 months of pregnancy (36). The CDC later clarified that women who have had a neural tube defect-affected pregnancy should consume 0.4 mg of folic acid per day unless they are planning a pregnancy (37). When these women are planning to become pregnant, they can follow the 1991 guideline and consult their physicians about the desirability of using 4.0 mg of folic acid per day (36; 37). Although a lower dose, such as 0.4 mg, may have as great a beneficial effect as 4.0 mg, women who are at very high risk of having a neural tube defect-affected pregnancy may choose to follow the August 1991 guideline (37; 48).

Consideration has been given to supplementing pregnant women with 5-methyltetrahydrofolate rather than folate because it does not require activation, is immediately available to mother and fetus, and does not accumulate in blood like folic acid does in cases of reduced hepatic transformation (52). However, the supposed benefits of 5-methyltetrahydrofolate over folate are of little clinical significance except in quite uncommon clinical circumstances. Certainly, there are no empiric comparative data in similar populations of women to support a change at this time.

Various anticonvulsants (eg, phenytoin, barbiturates) adversely affect folate levels, apparently by interfering with folate absorption, and, in turn, low blood folate levels in pregnant women taking anticonvulsants are associated with abnormal pregnancy outcomes (118; 44).

Oral contraceptives also impair folate metabolism, although this is unlikely to cause anemia or megaloblastic changes in women with either good dietary folate intake or folate supplementation (131). Nevertheless, prior use of the pill may compound the tendency of pregnant women to develop folate deficiency. Therefore, women who discontinue oral contraceptives and continue to be sexually active should take folate supplements before becoming pregnant (131).

Mothers with polymorphisms in folate-homocysteine pathway genes are more likely to have children with Down syndrome, a genotypic risk that may potentially be mitigated by periconceptional nutritional supplementation (141).

Media

References

01: Ahmad I, Mukhtar G, Iqbal J, Ali SW. Hereditary folate malabsorption with extensive intracranial calcification. Indian Pediatr 2015;52(1):67-8. PMID 25638192
02: Ahmed SF, Ali MM, Kheiri S, Elzaki SEG, Adam I. Association of methylenetetrahydrofolate reductase C677T and reduced-f carrier-1 G80A gene polymorphism with preeclampsia in Sudanese women. Hypertens Pregnancy 2020;39(2):77-81. PMID 32013623
03: Alam C, Hoque MT, Finnell RH, Goldman ID, Bendayan R. Regulation of reduced folate carrier (RFC) by vitamin D receptor at the blood-brain barrier. Mol Pharm 2017;14(11):3848-58. PMID 28885847
04: Alata Jimenez N, Torres Pérez SA, Sánchez-Vásquez E, Fernandino JI, Strobl-Mazzulla PH. Folate deficiency prevents neural crest fate by disturbing the epigenetic Sox2 repression on the dorsal neural tube. Dev Biol 2018;444 Suppl 1:S193-S201. PMID 30098999
05: Allen LH. B vitamins: proposed fortification levels for complementary foods for young children. J Nutr 2003;133(9):3000S-7S. PMID 12949400
06: Allen LH. B vitamins in breast milk: relative importance of maternal status and intake, and effects on infant status and function. Adv Nutr 2012;3(3):362-9. PMID 22585913
07: Aluri S, Zhao R, Lubout C, Goorden SMI, Fiser A, Goldman ID. Hereditary folate malabsorption due to a mutation in the external gate of the proton-coupled folate transporter SLC46A1. Blood Adv 2018;2(1):61-8. PMID 29344585
08: Angier RB, Boothe JH, Hutchings BL, et al. The structure and synthesis of the liver L. casei factor. Science 1946;103:667-9. PMID 20982775
09: Anonymous. Lucy Wills. Lancet 1964;1(7344):1225-6. PMID 14132674
10: Araujo JR, Martel F, Borges N, Araújo JM, Keating E. Folates and aging: Role in mild cognitive impairment, dementia and depression. Ageing Res Rev 2015;22:9-19. PMID 25939915
11: Arias LD, Parra BE, Muñoz AM, Cárdenas DL, Duque TG, Manjarrés LM. Study exploring the effects of daily supplementation with 400 μg of folic acid on the nutritional status of folate in women of reproductive age. Birth Defects Res 2017;109(8):564-73. PMID 28398657
12: Ars CL, Nijs IM, Marroun HE, et al. Prenatal folate, homocysteine and vitamin B12 levels and child brain volumes, cognitive development and psychological functioning: the Generation R study. Br J Nutr 2019;122(s1):S1-9. PMID 31638501
13: Ashraf MJ, Cook JR, Rothberg MB. Clinical utility of folic acid testing for patients with anemia or dementia. J Gen Intern Med 2008;23(6):824-6. PMID 18414954
14: Ayaz R, Asoglu MR. Neural tube defects in eastern Turkey: is low folate status or vitamin B12 deficiency or both associated with a high rate of NTDs? J Matern Fetal Neonatal Med 2020;33(22):3835-40. PMID 31122096
15: Banjari I, Matoković V, Škoro V. The question is whether intake of folic acid from diet alone during pregnancy is sufficient. Med Pregl 2014;67(9-10):313-21. PMID 25546978
16: Barley SL, Mathers N. An audit of the care of post-gastrectomy patients. J R Coll Gen Pract 1980;30(215):365-70. PMID 7411520
17: Barnabe A, Aléssio AC, Bittar LF, et al. Folate, vitamin B12 and homocysteine status in the post-folic acid fortification era in different subgroups of the Brazilian population attended to at a public health care center. Nutr J 2015;14:19. PMID 25886278
18: Baroni L, Bonetto C, Rizzo G, Bertola C, Caberlotto L, Bazzerla G. Association between cognitive impairment and vitamin B12, folate, and homocysteine status in elderly adults: a retrospective study. J Alzheimers Dis 2019;70(2):443-53. PMID 31177227
19: Bastian H. Lucy Wills (1888-1964): the life and research of an adventurous independent woman. J R Coll Physicians Edinb 2008;38(1):89-91. PMID 19069045
20: Bazuin I, Pouwels S, Houterman S, Nienhuijs SW, Smulders JF, Boer AK. Improved and more effective algorithms to screen for nutrient deficiencies after bariatric surgery. Eur J Clin Nutr 2017;71(2):198-202. PMID 27966567
21: Bergamaschi G, Markopoulos K, Albertini R, et al. Anemia of chronic disease and defective erythropoietin production in patients with celiac disease. Haematologica 2008;93(12):1785-91. PMID 18815191
22: Bergen NE, Jaddoe VW, Timmermans S, et al. Homocysteine and folate concentrations in early pregnancy and the risk of adverse pregnancy outcomes: the Generation R Study. BJOG 2012;119(6):739-51. PMID 22489763
23: Berry RJ, Mulinare J, Hamner HC. Folic acid fortification. Neural tube defect risk reduction - a global perspective. In: Bailey LB, editor. Folate in health and disease. Boca Raton: CRC Press, 2010:179-204.
24: Bjerregaard VA, Garribba L, McMurray CT, Hickson ID, Liu Y. Folate deficiency drives mitotic missegregation of the human FRAXA locus. Proc Natl Acad Sci U S A 2018;115(51):13003-8. PMID 30509972
25: Binia A, Contreras AV, Canizales-Quinteros S, Alonzo VA, Tejero ME, Silva-Zolezzi I. Geographical and ethnic distribution of single nucleotide polymorphisms within genes of the folate/homocysteine pathway metabolism. Genes Nutr 2014;9(5):421. PMID 25106483
26: Bjørkevoll SM, Konijnenberg C, Kvestad I, et al. Vitamin B12 and folate status in pregnant females and their infants in Norway: secondary analysis from the Mommy's Food Study. J Nutr 2023;153(12):3543-54. PMID 37858724
27: Botez MI, Peyronnard JM, Bérubé L, Labrecque R. Relapsing neuropathy, cerebral atrophy and folate deficiency. A close association. Appl Neurophysiol 1979;42(3):171-83. PMID 464598
28: Budd M, Naugler C. Folate deficiency in an unselected population in Calgary, Alberta and its relationship with red blood cell macrocytosis. BMC Res Notes 2015;8:314. PMID 26208501
29: Burr NE, Hull MA, Subramanian V. Folic acid supplementation may reduce colorectal cancer risk in patients with inflammatory bowel disease: a systematic review and meta-analysis. J Clin Gastroenterol 2017;51(3):247-53. PMID 26905603
30: Cai CQ, Fang YL, Shu JB, et al. Association of neural tube defects with maternal alterations and genetic polymorphisms in one-carbon metabolic pathway. Ital J Pediatr 2019;45(1):37. PMID 30867013
31: Calvani M Jr, Parisi P, Guaitolini C, Parisi G, Paolone G. Latent coeliac disease in a child with epilepsy, cerebral calcifications, drug-induced systemic lupus erythematosus and intestinal folic acid malabsorption associated with impairment of folic acid transport across the blood-brain barrier. Eur J Pediatr 2001;160(5):288-92. PMID 11388596
32: Cantarella CD, Ragusa D, Giammanco M, Tosi S. Folate deficiency as predisposing factor for childhood leukaemia: a review of the literature. Genes Nutr 2017;12:14. PMID 28588742
33: Cario H, Bode H, Debatin KM, Opladen T, Schwarz K. Congenital null mutations of the FOLR1 Gene: a progressive neurologic disease and its treatment. Neurology 2009;73(24):2127-9. PMID 20018644
34: Carmel R. Folate deficiency. In: Carmel R, Jacobsen DW, editors. Homocysteine in health and disease. Cambridge: Cambridge University Press, 2001:271-88.
35: Catov JM, Bodnar LM, Ness RB, Markovic N, Roberts JM. Association of periconceptional multivitamin use and risk of preterm or small-for-gestational-age births. Am J Epidemiol 2007;166(3):296-303. PMID 17496313
36: Centers for Disease Control and Prevention. Use of folic acid for prevention of spina bifida and other neural tube defects--1983-1991. MMWR Morb Mortal Wkly Rep 1991;40(30):513-6. PMID 2072886
37: Centers for Disease Control and Prevention. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Recomm Rep 1992;41(RR-14):1-7. PMID 1522835
38: Centers for Disease Control and Prevention. Spina bifida and anencephaly before and after folic acid mandate--United States, 1995-1996 and 1999-2000. MMWR Morb Mortal Wkly Rep 2004;53(17):362-5. PMID 15129193
39: Chang S, Lu X, Wang S, et al. The effect of folic acid deficiency on FGF pathway via Brachyury regulation in neural tube defects. FASEB J 2019;33(4):4688-702. PMID 30592646
40: Chilukuri N, Bustamante-Helfrich B, Ji Y, et al. Maternal folate status and placental vascular malperfusion: Findings from a high-risk US minority birth cohort. Placenta 2022;129:87-93. PMID 36274480
41: Christensen KE, Rozen R. Genetic variation. Effect on folate metabolism and health. In: Bailey LB, editor. Folate in health and disease. 2nd edition. Boca Raton: CRC Press, 2010:75-110.
42: Conzade R, Koenig W, Heier M, et al. Prevalence and predictors of subclinical micronutrient deficiency in German older adults: results from the population-based KORA-Age Study. Nutrients 2017;9(12). PMID 29168737
43: Corbeel L, Van den Berghe G, Jaeken J, Van Tornout J, Eeckels R. Congenital folate malabsorption. Eur J Pediatr 1985;143(4):284-90. PMID 3987728
44: Dansky LV, Andermann E, Rosenblatt D, Sherwin AL, Andermann F. Anticonvulsants, folate levels, and pregnancy outcome: a prospective study. Ann Neurol 1987;21(2):176-82. PMID 3827226
45: Delmelle F, Thöny B, Clapuyt P, Blau N, Nassogne MC. Neurological improvement following intravenous high-dose folinic acid for cerebral folate transporter deficiency caused by FOLR-1 mutation. Eur J Paediatr Neurol 2016;20(5):709-13. PMID 27328863
46: Deopa B, Parakh M, Dara P, et al. Effect of folic acid supplementation on seizure control in epileptic children receiving long term antiepileptic therapy. Indian J Pediatr 2018;85(7):493-7. PMID 29368110
47: Desai A, Sequeira JM, Quadros EV. The metabolic basis for developmental disorders due to defective folate transport. Biochimie 2016;126:31-42. PMID 26924398
48: Dolin CD, Deierlein AL, Evans MI. Folic acid supplementation to prevent recurrent neural tube defects: 4 milligrams is too much. Fetal Diagn Ther 2018;44(3):161-5. PMID 30134243
49: Enk C, Hougaard K, Hippe E. Reversible dementia and neuropathy associated with folate deficiency 16 years after partial gastrectomy. Scand J Haematol 1980;25(1):63-6. PMID 6255553
50: Erlacher M, Grünert SC, Cseh A, et al. Reversible pancytopenia and immunodeficiency in a patient with hereditary folate malabsorption. Pediatr Blood Cancer 2015;62(6):1091-4. PMID 25504888
51: Estivariz CF, Luo M, Umeakunne K, et al. Nutrient intake from habitual oral diet in patients with severe short bowel syndrome living in the southeastern United States. Nutrition 2008;24(4):330-9. PMID 18328409
52: Ferrazzi E, Tiso G, Di Martino D. Folic acid versus 5- methyl tetrahydrofolate supplementation in pregnancy. Eur J Obstet Gynecol Reprod Biol 2020;253:312-9. PMID 32868164
53: Findley TO, Tenpenny JC, O'Byrne MR, et al. Mutations in folate transporter genes and risk for human myelomeningocele. Am J Med Genet A 2017;173(11):2973-84. PMID 28948692
54: Fox JT, Stover PJ. Folate-mediated one-carbon metabolism. Vitam Horm 2008;79:1-44. PMID 18804690
55: Fu J, Liu Q, Zhu Y, et al. Circulating folate concentrations and the risk of mild cognitive impairment: A prospective study on the older Chinese population without folic acid fortification. Eur J Neurol 2022;29(10):2913-24. PMID 35735052
56: Furness DL, Yasin N, Dekker GA, Thompson SD, Roberts CT. Maternal red blood cell folate concentration at 10-12 weeks gestation and pregnancy outcome. J Matern Fetal Neonatal Med 2012;25(8):1423-7. PMID 22081889
57: Furness D, Fenech M, Dekker G, Khong TY, Roberts C, Hague W. Folate, vitamin B12, vitamin B6 and homocysteine: impact on pregnancy outcome. Matern Child Nutr 2013;9(2):155-66. PMID 22023381
58: Gebremichael B, Roba HS, Getachew A, Tesfaye D, Asmerom H. Folate deficiency among women of reproductive age in Ethiopia: A systematic review and meta-analysis. PLoS One 2023;18(5):e0285281. PMID 37155667
59: Geller J, Kronn D, Jayabose S, Sandoval C. Hereditary folate malabsorption: family report and review of the literature. Medicine 2002;81:51-68. PMID 11807405
60: Golja VM, Smid A, Karas Kuželički N, Trontelj J, Geršak K, Mlinarič-Raščan I. Folate insufficiency due to MTHFR deficiency is bypassed by 5-methyltetrahydrofolate. J Clin Med 2020;9(9):2836. PMID 32887268
61: Gilfix BM. Utility of measuring serum or red blood cell folate in the era of folate fortification of flour. Clin Biochem 2014;47(7-8):533-8. PMID 24486651
62: Godfrey KM, Titcombe P, El-Heis S, Aet al. Maternal B-vitamin and vitamin D status before, during, and after pregnancy and the influence of supplementation preconception and during pregnancy: Prespecified secondary analysis of the NiPPeR double-blind randomized controlled trial. PLoS Med 2023;20(12):e1004260. PMID 38051700
63: Grapp M, Just IA, Linnankivi T, et al. Molecular characterization of folate receptor 1 mutations delineates cerebral folate transport deficiency. Brain 2012;135(Pt 7):2022-31. PMID 22586289
64: Gudgeon P, Cavalcanti R. Folate testing in hospital inpatients. Am J Med 2015;128(1):56-9. PMID 25196989
65: Guo X, Ni J, Zhu Y, Zhou T, Ma X, Xue J, Wang X. Folate deficiency induces mitotic aberrations and chromosomal instability by compromising the spindle assembly checkpoint in cultured human colon cells. Mutagenesis 2017;32(6):547-60. PMID 29165592
66: Halstead CH. In memoriam: Victor Herbert, MD 1927-2002. Am J Clin Nutr 2003;77:757-9. PMID 12663267
67: Halsted CH, Reisenauer AM, Romero JJ, Cantor DS, Ruebner B. Jejunal perfusion of simple and conjugated folates in celiac sprue. J Clin Invest 1977;59(5):933-40. PMID 856874
68: Halsted CH, Villanueva JA, Devlin AM, Chandler CJ. Metabolic interactions of alcohol and folate. J Nutr 2002;132(8 Suppl):2367S-72S. PMID 12163694
69: Hama Y, Hamano T, Shirafuji N, et al. Influences of folate supplementation on homocysteine and cognition in patients with folate deficiency and cognitive impairment. Nutrients 2020;12(10):3138. PMID 33066591
70: Hay G, Clausen T, Whitelaw A, et al. Maternal folate and cobalamin status predicts vitamin status in newborns and 6-month-old infants. J Nutr 2010;140(3):557-64. PMID 20071650
71: Henderson AM, Aleliunas RE, Loh SP, et al. l-5-Methyltetrahydrofolate supplementation increases blood folate concentrations to a greater extent than folic acid supplementation in Malaysian women. J Nutr 2018;148(6):885-90. PMID 29878267
72: Herbert V. Experimental nutritional folate deficiency in man. Trans Assoc Am Physicians 1962;75:307-20. PMID 13953904
73: Hildebrand LA, Dumas B, Milrod CJ, Hudspeth JC. Folate deficiency in an urban safety net population. Am J Med 2021;134(10):1265-9. PMID 34051149
74: Hoffbrand AV, Douglas AP, Fry L, Stewart JS. Malabsorption of dietary folate (Pteroylpolyglutamates) in adult coeliac disease and dermatitis herpetiformis. Br Med J 1970;4(5727):85-9. PMID 5471775
75: Hoffbrand AV, Necheles TF, Maldonado N, Horta E, Santini R. Malabsorption of folate polyglutamates in tropical sprue. Br Med J 1969;2(5656):543-7. PMID 5769888
76: Institute of Medicine. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin b6, folate, vitamin b12, pantothenic acid, biotin, and choline. Washington, DC: The National Academies Press, 1998.
77: Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7-9. PMID 8616944
78: James SJ, Pogribna M, Pogribny IP, et al. Abnormal folate metabolism and mutation in the methylenetetrahydrofolate reductase gene may be maternal risk factors for Down syndrome. Am J Clin Nutr 1999;70(4):495-501. PMID 10500018
79: Jani R, Salian N, Udipi S, et al. Folate status and intake of tribal Indian adolescents aged 10 to 17 years. Food Nutr Bull 2015;36(1):14-23. PMID 25898712
80: Jennings BA, Willis G. How folate metabolism affects colorectal cancer development and treatment; a story of heterogeneity and pleiotropy. Cancer Lett 2015;356(2 Pt A):224-30. PMID 24614284
81: Karin I, Borggraefe I, Catarino CB, et al. Folinic acid therapy in cerebral folate deficiency: marked improvement in an adult patient. J Neurol 2017;264(3):578-82. PMID 28054128
82: Kayal AK, Goswami M, Das M, Basumatary LJ, Bhowmick SS, Synmon B. Etiological profile of noncompressive myelopathies in a tertiary care hospital of Northeast India. Ann Indian Acad Neurol 2017;20(1):41-50. PMID 28298841
83: Kennedy D, Koren G. Identifying women who might benefit from higher doses of folic acid in pregnancy. Can Fam Physician 2012;58(4):394-7. PMID 22499814
84: Kishimoto K, Kobayashi R, Sano H, et al. Impact of folate therapy on combined immunodeficiency secondary to hereditary folate malabsorption. Clin Immunol 2014;153(1):17-22. PMID 24691418
85: Klee GG. Cobalamin and folate evaluation: measurement of methylmalonic acid and homocysteine vs vitamin B(12) and folate. Clin Chem 2000;46(8 Pt 2):1277-83. PMID 10926922
86: Kobayashi Y, Tohyama J, Akiyama T, et al. Severe leukoencephalopathy with cortical involvement and peripheral neuropathy due to FOLR1 deficiency. Brain Dev 2017;39(3):266-70. PMID 27743887
87: Koike H, Nakamura T, Ikeda S, et al. Alcoholic myelopathy and nutritional deficiency. Intern Med 2017;56(1):105-8. PMID 28049986
88: Koike H, Takahashi M, Ohyama K, et al. Clinicopathologic features of folate-deficiency neuropathy. Neurology 2015;84(10):1026-33. PMID 25663227
89: Kvalsund M, Kayamba V, Kelly P, et al. Is folate deficiency a common cause of distal symmetric polyneuropathy in Zambian clinics? J Neurol Sci 2020;409:116583. PMID 31864072
90: Lanska DJ. Historical aspects of the major neurological vitamin deficiency disorders: the water-soluble B vitamins. In: Boller F, Finger S, Tyler KL, editors. History of neurology (Handbook of clinical neurology. Third series.). Amsterdam: Elsevier Science Publishing Co., 2010;95:445-76.
91: Laurence KM, James N, Miller MH, Tennant GB, Campbell H. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. Br Med J (Clin Res Ed) 1981;282(6275):1509-11. PMID 6786536
92: Li J, Xie Q, Gao J, et al. Aberrant Gcm1 expression mediates Wnt/β-catenin pathway activation in folate deficiency involved in neural tube defects. Cell Death Dis 2021;12(3):234. PMID 33664222
93: Li X, Hu Y, Shi X, Zhu X, Liu F. Prevalence and relevant factors of micronutrient deficiencies in hospitalized patients with inflammatory bowel disease. Nutrition 2022;99-100:111671. PMID 35551017
94: Liu C, Luo D, Wang Q, et al. Serum homocysteine and folate concentrations in early pregnancy and subsequent events of adverse pregnancy outcome: the Sichuan Homocysteine study. BMC Pregnancy Childbirth 2020;20(1):176. PMID 32188414
95: López-Quesada E, Vilaseca MA, Lailla JM. Plasma total homocysteine in uncomplicated pregnancy and in preeclampsia. Eur J Obstet Gynecol Reprod Biol 2003;108(1):45-9. PMID 12694969
96: Lossos A, Argov Z, Ackerman Z, Abramsky O. Peripheral neuropathy and folate deficiency as the first sign of Crohn's disease. J Clin Gastroenterol 1991;13(4):442-4. PMID 1655863
97: Luhby AL, Eagle FJ, Roth E, Cooperman AJ. Relapsing megaloblastic anemia in an infant due to a specific defect in gastrointestinal absorption of folic acid. Am J Dis Child 1961;102:482-3.
98: Malatack JJ, Moran MM, Moughan B. Isolated congenital malabsorption of folic acid in a male infant: insights into treatment and mechanism of defect. Pediatrics 1999;104(5 Pt 1):1133-7. PMID 10545560
99: Martinez Figueroa A, Johnson RH, Lambie DG, Shakir RA. The role of folate deficiency in the development of peripheral neuropathy caused by anticonvulsants. J Neurol Sci 1980;48(3):315-23. PMID 6255104
100: McNulty H, Ward M, Hoey L, Hughes CF, Pentieva K. Addressing optimal folate and related B-vitamin status through the lifecycle: health impacts and challenges. Proc Nutr Soc 2019;78(3):449-62. PMID 31155015
101: Medici V, Halsted CH. Folate, alcohol, and liver disease. Mol Nutr Food Res 2013;57(4):596-606. PMID 23136133
102: Montgomery RD, Beale DJ, Sammons HG, Schneider R. Postinfective malabsorption: a sprue syndrome. Br Med J 1973;2(5861):265-8. PMID 4513055
103: MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991;338(8760):131-7. PMID 1677062
104: Na HK, Lee JY. Molecular basis of alcohol-related gastric and colon cancer. Int J Mol Sci 2017;18(6). PMID 28538665
105: Naderi N, House JD. Recent developments in folate nutrition. Adv Food Nutr Res 2018;83:195-213. PMID 29477222
106: Obaji SG, Al-Ismail S. Isolated folate deficiency causing profound pancytopenia in pregnancy. BMJ Case Rep 2015;2015:bcr2014207861. PMID 25666248
107: Obeid R, Schön C, Wilhelm M, Pietrzik K, Pilz S. The effectiveness of daily supplementation with 400 or 800 µg/day folate in reaching protective red blood folate concentrations in non-pregnant women: a randomized trial. Eur J Nutr 2018;57(5):1771-80. PMID 28447203
108: Odewole OA, Williamson RS, Zakai NA, et al. Near-elimination of folate-deficiency anemia by mandatory folic acid fortification in older US adults: Reasons for Geographic and Racial Differences in Stroke study 2001-2007. Am J Clin Nutr 2013;98(4):1042-7. PMID 23945721
109: Okazaki Y, Watabu T, Endo K, Oiwa H. Hypersegmented neutrophils in methotrexate toxicity. Intern Med 2018;57(7):1055-6. PMID 29269671
110: Olapeju B, Ahmed S, Hong X, et al. Maternal hypertensive disorders in pregnancy and postpartum plasma B vitamin and homocysteine profiles in a high-risk multiethnic U.S., population. J Womens Health (Larchmt) 2020;29(12):1520-9. PMID 33252313
111: Olapeju B, Saifuddin A, Wang G, et al. Maternal postpartum plasma folate status and preterm birth in a high-risk US population. Public Health Nutr 2019;22(7):1281-91. PMID 30486913
112: Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol 2015;4(3):215-66. PMID 25772309
113: Osunkalu VO, Taiwo IA, Makwe CC, Quao RA. Methylene tetrahydrofolate reductase and methionine synthase gene polymorphisms as genetic determinants of pre-eclampsia. Pregnancy Hypertens 2020;20:7-13. PMID 32120336
114: Padhi S, Sarangi R, Ramdas A, et al. Cutaneous hyperpigmentation in megaloblastic anemia: a five year retrospective review. Mediterr J Hematol Infect Dis 2016;8(1):e2016021. PMID 27158434
115: Poncz M, Cohen A. Long-term treatment of congenital folate malabsorption. J Pediatr 1996;129(6):948. PMID 8969750
116: Poncz M, Colman N, Herbert V, Schwartz E, Cohen A. Congenital folate malabsorption. J Pediatr 1981a;99(5):828-9. PMID 7299568
117: Poncz M, Colman N, Herbert V, Schwartz E, Cohen AR. Therapy of congenital folate malabsorption. J Pediatr 1981b;98(1):76-9. PMID 6969796
118: Pritchard JA, Scott DE, Whalley PJ. Maternal folate deficiency and pregnancy wastage. IV. Effects of folic acid supplements, anticonvulsants, and oral contraceptives. Am J Obstet Gynecol 1971;109(3):341-6. PMID 5549181
119: Qiu A, Jansen M, Sakaris A, et al. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006;127:917-28. PMID 17129779
120: Rajkovic A, Mahomed K, Rozen R, Malinow MR, King IB, Williams MA. Methylenetetrahydrofolate reductase 677 C --> T polymorphism, plasma folate, vitamin B(12) concentrations, and risk of preeclampsia among black African women from Zimbabwe. Mol Genet Metab 2000;69(1):33-9. PMID 10655155
121: Ramaekers VT, Sequeira JM, Quadros EV. The basis for folinic acid treatment in neuro-psychiatric disorders. Biochimie 2016;126:79-90. PMID 27068282
122: Reynolds E. The neurology of folic acid deficiency. Handb Clin Neurol 2014;120:927-43. PMID 24365361
123: Rodrigues HG, Gubert MB, Santos LM. Folic acid intake by pregnant women from Vale do Jequitinhonha, Brazil, and the contribution of fortified foods. Arch Latinoam Nutr 2015;65(1):27-35. PMID 26320303
124: Roe DA. Lucy Wills (1888-1964). A biographical sketch. J Nutr 1978;108(9):1379-83. PMID 355606
125: Rosenthal J, Lopez-Pazos E, Dowling NF, et al. Folate and vitamin B12 deficiency among non-pregnant women of childbearing-age in Guatemala 2009-2010: prevalence and identification of vulnerable populations. Matern Child Health J 2015;19(10):2272-85. PMID 26002178
126: Rotstein A, Kodesh A, Goldberg Y, Reichenberg A, Levine SZ. Serum folate deficiency and the risks of dementia and all-cause mortality: a national study of old age. Evid Based Ment Health 2022;25(2):63-8. PMID 35292483
127: Samodelov SL, Gai Z, Kullak-Ublick GA, Visentin M. Renal reabsorption of folates: pharmacological and toxicological snapshots. Nutrients 2019;11(10):2353. PMID 31581752
128: Sanvisens A, Zuluaga P, Pineda M, et al. Folate deficiency in patients seeking treatment of alcohol use disorder. Drug Alcohol Depend 2017;180:417-22. PMID 28988003
129: Shin DS, Mahadeo K, Min SH, et al. Identification of novel mutations in the proton-coupled folate transporter (PCFT-SLC46A1) associated with hereditary folate malabsorption. Mol Genet Metab 2011;103:33-7. PMID 21333572
130: Shin DS, Zhao R, Fiser A, Goldman DI. Functional roles of the A335 and G338 residues of the proton-coupled folate transporter (PCFT-SLC46A1) mutated in hereditary folate malabsorption. Am J Physiol Cell Physiol 2012;303(8):C834-42. PMID 22843796
131: Shojania AM. Oral contraceptives: effect of folate and vitamin B12 metabolism. Can Med Assoc J 1982;126(3):244-7. PMID 7037144
132: Shorvon SD, Carney MW, Chanarin I, Reynolds EH. The neuropsychiatry of megaloblastic anaemia. Br Med J 1980;281:1036-8. PMID 6253016
133: Shulpekova Y, Nechaev V, Kardasheva S, Sedova A, et al. The concept of folic acid in health and disease. Molecules 2021;26(12):3731. PMID 34207319
134: Slagman A, Harriss L, Campbell S, Muller R, McDermott R. Low proportions of folic acid deficiency after introduction of mandatory folic acid fortification in remote areas of northern Queensland, Australia: a secondary health data analysis. Biomarkers 2019;24(7):684-91. PMID 31382779
135: Sobczynska-Malefora A, Harrington DJ. Laboratory assessment of folate (vitamin B(9)) status. J Clin Pathol 2018;71(11):949-56. PMID 30228213
136: Sofer Y, Harel L, Sharkia M, Amir J, Schoenfeld T, Straussberg R. Neurological manifestations of folate transport defect: case report and review of the literature. J Child Neurol 2007;22(6):783-6. PMID 17641272
137: Song S, Song BM, Park HY. Associations of serum folate and homocysteine concentrations with all-cause, cardiovascular disease, and cancer mortality in men and women in Korea: the Cardiovascular Disease Association Study. J Nutr 2023;153(3):760-70. PMID 36792392
138: Stark GL, Hamilton PJ. Dietary folate deficiency with normal red cell folate and circulating blasts. J Clin Pathol 2003;56(4):313-5. PMID 12663648
139: Steinfeld R, Grapp M, Kraetzner R, et al. Folate receptor alpha defect causes cerebral folate transport deficiency: a treatable neurodegenerative disorder associated with disturbed myelin metabolism. Am J Hum Genet 2009;85(3):354-63. PMID 19732866
140: Steinschneider M, Sherbany A, Pavlakis S, Emerson R, Lovelace R, De Vivo DC. Congenital folate malabsorption: reversible clinical and neurophysiologic abnormalities. Neurology 1990;40(8):1315. PMID 2381546
141: Sukla KK, Jaiswal SK, Rai AK, et al. Role of folate-homocysteine pathway gene polymorphisms and nutritional cofactors in Down syndrome: a triad study. Hum Reprod 2015;30(8):1982-93. PMID 26040482
142: Tamura T, Picciano MF. Folate and human reproduction. Am J Clin Nutr 2006;83(5):993-1016. PMID 16685040
143: Tan J, Li X, Guo Y, et al. Hereditary folate malabsorption with a novel mutation on SLC46A1: a case report. Medicine (Baltimore) 2017;96(50):e8712. PMID 29390264
144: Taverner T, Crowe FL, Thomas GN, et al. Circulating folate concentrations and risk of peripheral neuropathy and mortality: a retrospective cohort study in the U.K. nutrients. 2019;11(10):2443. PMID 31614995
145: Teven CM, Farina EM, Rivas J, Reid RR. Fibroblast growth factor (FGF) signaling in development and skeletal diseases. Genes Dis 2014;1(2):199-213. PMID 25679016
146: Thériault S, Giguère Y, Massé J, et al. Absence of association between serum folate and preeclampsia in women exposed to food fortification. Obstet Gynecol 2013;122(2 Pt 1):345-351. PMID 23969804
147: Tomkins AM, James WP, Walters JH, Cole AC. Malabsorption in overland travellers to India. Br Med J 1974;3(5927):380-4. PMID 4853071
148: Torres A, Newton SA, Crompton B, et al. CSF 5-Methyltetrahydrofolate serial monitoring to guide treatment of congenital folate malabsorption due to proton-coupled folate transporter (PCFT) deficiency. JIMD Rep 2015;24:91-6. PMID 26006721
149: Tu HC, Lee GH, Hsiao TH, et al. One crisis, diverse impacts-tissue-specificity of folate deficiency-induced circulation defects in zebrafish larvae. PLoS One 2017;12(11):e0188585. PMID 29176804
150: US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Folic acid supplementation for the prevention of neural tube defects: US Preventive Services Task Force Recommendation Statement. JAMA 2017;317(2):183-9. PMID 28097362
151: Vanderlelie J, Scott R, Shibl R, Lewkowicz J, Perkins A, Scuffham PA. First trimester multivitamin/mineral use is associated with reduced risk of pre-eclampsia among overweight and obese women. Matern Child Nutr 2016;12(2):339-48. PMID 24847942
152: Via MA, Mechanick JI. Nutritional and micronutrient care of bariatric surgery patients: current evidence update. Curr Obes Rep 2017;6(3):286-96. PMID 28718091
153: Vidmar M, Grželj J, Mlinarič-Raščan I, Geršak K, Dolenc MS. Medicines associated with folate-homocysteine-methionine pathway disruption. Arch Toxicol 2019;93(2):227-51. PMID 30499019
154: Viswanathan M, Treiman KA, Kish-Doto J, Middleton JC, Coker-Schwimmer EJ, Nicholson WK. Folic acid supplementation for the prevention of neural tube defects: an updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2017;317(2):190-203. PMID 28097361
155: Visentin M, Diop-Bove N, Zhao R, Goldman ID. The intestinal absorption of folates. Annu Rev Physiol 2014;76:251-74. PMID 24512081
156: Vollset SE, Refsum H, Irgens LM, et al. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine study. Am J Clin Nutr 2000;71(4):962-8. PMID 10731504
157: Wadsworth GR. Tropical macrocytic anaemia: the investigations of Lucy Wills in India. Asia Pac J Public Health 1988;2(4):265-73. PMID 3052544
158: Wang L, Shangguan S, Xin Y, et al. Folate deficiency disturbs hsa-let-7 g level through methylation regulation in neural tube defects. J Cell Mol Med 2017;21(12):3244-53. PMID 28631291
159: Wang Q, Li X, Ding Y, Liu Y, Qin Y, Yang Y. The first Chinese case report of hereditary folate malabsorption with a novel mutation on SLC46A1. Brain Dev 2015a;37(1):163-7. PMID 24534056
160: Wang Y, Zhao N, Qiu J, et al. Folic acid supplementation and dietary folate intake, and risk of preeclampsia. Eur J Clin Nutr 2015b;69(10):1145-50. PMID 25626412
161: Wen SW, Chen XK, Rodger M, et al. Folic acid supplementation in early second trimester and the risk of preeclampsia. Am J Obstet Gynecol 2008;198(1):45.e1-7. PMID 18166303
162: Whitehead VM. Acquired and inherited disorders of cobalamin and folate in children. Br J Haematol 2006;134(2):125-36. PMID 16846473
163: Williams J, Mai CT, Mulinare J, et al. Updated estimates of neural tube defects prevented by mandatory folic acid fortification--United States, 1995-2011. MMWR Morb Mortal Wkly Rep 2015;64(1):1-5. PMID 25590678
164: Wills L. Treatment of "pernicious anaemia of pregnancy" and "tropical anaemia.” Br Med J 1931;1(3676):1059-64. PMID 20776230
165: Wu X, Yang K, Tang X, et al. Folate metabolism gene polymorphisms MTHFR C677T and A1298C and risk for preeclampsia: a meta-analysis. J Assist Reprod Genet 2015;32(5):797-805. PMID 25758986
166: Yan WJ, Yu N, Yin TL, Zou YJ, Yang J. A new potential risk factor in patients with erectile dysfunction and premature ejaculation: folate deficiency. Asian J Androl 2014;16(6):902-6. PMID 25080932
167: Zhang D, Wen X, Wu W, Guo Y, Cui W. Elevated homocysteine level and folate deficiency associated with increased overall risk of carcinogenesis: meta-analysis of 83 case-control studies involving 35,758 individuals. PLoS One 2015;10(5):e0123423. PMID 25985325
168: Zhao R, Aluri S, Goldman ID. The proton-coupled folate transporter (PCFT-SLC46A1) and the syndrome of systemic and cerebral folate deficiency of infancy: hereditary folate malabsorption. Mol Aspects Med 2017;53:57-72. PMID 27664775
169: Zhao R, Goldman ID. Folate and thiamine transporters mediated by facilitative carriers (SLC19A1-3 and SLC46A1) and folate receptors. Mol Aspects Med 2013;34(2-3):373-85. PMID 23506878
170: Zhao R, Min SH, Qiu A, et al. The spectrum of mutations in the PCFT gene, coding for an intestinal folate transporter, that are the basis for hereditary folate malabsorption. Blood 2007;110:1147-52. PMID 17446347
171: Zhilyaeva TV, Sergeeva AV, Blagonravova AS, et al. Association study of methylenetetrahydrofolate reductase genetic polymorphism 677C>T with schizophrenia in hospitalized patients in population of European Russia. Asian J Psychiatr 2018;32:29-33.** PMID 29202425
172: Zhou Z, Li J, Yu Y, et al. Effect of smoking and folate levels on the efficacy of folic acid therapy in prevention of stroke in hypertensive men. Stroke 2018;49(1):114-20.** PMID 29273594

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Douglas J Lanska MD MS MSPH

Dr. Lanska of the University of Wisconsin School of Medicine and Public Health and the Medical College of Wisconsin has no relevant financial relationships to disclose.
See Profile

Former Authors

David Watkins PhD
David S Rosenblatt MD

Patient Profile

Age range of presentation: 1 month to 65+ years
Sex preponderance: female>male, >1:1
Heredity: heredity may be a factor

autosomal recessive (hereditary folate malabsorption)
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Folate deficiency anemia: D52

Deficiency of other specified B group vitamins: E53.8
ICD-11: Folate deficiency: 5B5E

Folate deficiency anaemia: 3A02
OMIM: Hereditary folate malabsorption: #229050

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Folate deficiency

Differential Diagnosis

vitamin B12 (cobalamin) deficiency

Also Relevant

Anencephaly and other neural tube defects
Cerebral folate deficiency
Hyperhomocysteinemia
Malformations of the brain
Nutrition and the brain
- Nutrition-related peripheral neuropathies
- Toxic and nutritional deficiency optic neuropathies
- Vitamin B12 deficiency

Clinical Categories

Neurogenetic Disorders

Folate deficiency

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Biological basis

Etiology and pathogenesis

Intestinal folate absorption

Folate cellular uptake

The folate cycle

Activated methyl cycle

Purine biosynthesis

Causes of folate deficiency

Table 1. Medications that Interfere with Folate-Homocysteine–Methionine Pathway

Table 2. Medications that Interfere with Folate Absorption, Utilization, or Elimination

Consequences of folate deficiency

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Outcomes

Special considerations

Pregnancy

Media

References

Contributors

Author

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Carnitine palmitoyltransferase II deficiency

Pyruvate carboxylase deficiency

Pelizaeus-Merzbacher disease

Vanishing white matter disease

Wilson disease

Aromatic L-amino acid decarboxylase deficiency

White matter abnormalities in the brain

Hypermethioninemia

This is an article preview.
Start a Free Account
to access the full version.